KR20150129190A - USE OF REV-ERBα FOR TREATING AFFECTIVE AND ADDICTIVE DISORDERS - Google Patents

Abstract

The present invention relates to a correlation between a dopamine synthesis system in a midbrain and a biological clock involving in a mechanism of regulating circadian rhythm. According to the present invention, by using a REV-ERBα protein for biological clock and a gene encoding the protein, it is possible to screen novel drug candidate materials for treating and/or preventing cerebropathy caused by an abnormal regulation of the dopamine system. In addition, the present invention may provide a pharmaceutical composition having effects of preventing and/or treating cerebropathy caused by the abnormal dopamine system regulation, by inhibiting REV-ERBα protein which is a nuclear receptor and the gene encoding the protein.

Description

Use of REV-ERBα gene for the treatment of emotional disorders and poisoning diseases (Use of REV-ERBα for treating affective and addictive disorders)

The present invention relates to the relationship between the biological clock gene involved in the periodic regulation mechanism and the midbrain dopamine synthesis pathway. The present invention relates to the discovery of useful biological clock molecule targets based on a periodic regulatory mechanism and the use thereof to treat emotional disorders and poisoning diseases through dopamine system control.

Circadian rhythm refers to any biological rhythm that occurs 24 hours a day in a living organism and involves a variety of physiological-behavioral processes including sleep-wake patterns, feeding, hormone secretion, body temperature changes, and metabolism. This rhythm is known to have a cycle of about one day even under certain environmental conditions in which information on time is excluded from the outside (Non-Patent Documents 1 and 2). In a mammal, including humans, CLOCK, BMAL1, PER1, PER2, PER3, CRY2, and REV - was identified various biological clock gene, including the ERB α are, they are transferred, the transfer end process, translation, post-translational processing, of the nucleus (Molecular oscillator) that produces a rhythm of gene expression close to 24 hours in the absence of external stimuli, with a positive or negative feedback loop through a series of processes, ). ≪ / RTI > The central clock (master clock) of mammals, including humans, is known to exist in the suprachiasmatic nucleus (SCN), a small area of the hypothalamus. However, the fact that most of the peripheral tissues and organs, including SCN, and the liver, lungs, muscles, and heart, express the same periodic gene as the central biological clock, suggests that molecular vibrators exist not only in each tissue or organ, Suggesting that it will operate as a peripheral clock or a local clock that produces organ-specific physiological-biochemical rhythms. Thus, the biological clock is a system in which the central clock present in the optic nerve crossing nucleus synchronizes the peripheral clock with the surrounding environment through the output of neural or humoral output, and the periodic change of the environment and the physiological-biochemical It is thought to have a hierarchical organization for rhythm harmony. Local molecular biological clocks found in various peripheral organs and SCNs contribute to the periodic implementation of specific physiological phenomena of each tissue by inducing periodic expression of various genes in a tissue specific pattern. For example, in a previous study, the present inventors found that the CLOCK: BMAL1 dimer, which is a core transcription factor of the adrenal gland's clock molecular machinery, in particular, the biological clock central circuit, induces the cyclic expression of the steroid synthesis genes in the adrenal cortex, (See Non-Patent Document 3). In addition, the present inventors have reported on the fact that they play a pivotal role in the daily cyclic synthesis and secretion of the cells. 2) RORs (REV-ERBs), which are nuclear receptors that make up the transcriptional regulation through the CLOCK: BMAL1 dimer and the auxiliary circuit of the biological clock, and the direct regulation of these biological clock transcription factors 3) Through secondary transcription factors such as DBP, it is known to regulate the cyclic expression of subgeneric genes. Therefore, it is believed that the interaction between these biological clock transcription factors and tissue - specific transcription factors constitutes the basis of the action mechanism of the periodic output by the local biomedical clock.

Recent studies using mutations and knockouts of day cycle genes have shown that when a cycle is linked to a gene that constitutes a molecular oscillator, various types of cardiovascular diseases such as cancer, obesity, type 2 diabetes as well as hypertension occur, And the pathological phenomena associated with the disease can be accelerated. In addition, various forms of circadian rhythm disorder were found to be associated with various emotional disorders such as depression, manic depression, seasonal mood disorder and panic disorder and early onset of various addictive disorders (diseases). In particular, diabetic rhythm abnormality is significantly observed in bipolar patients with high genetic susceptibility, for example, patients with acute mania show extreme confused sleep-wake cycles, and sleep deprivation precedes mania It is very frequent. In addition, recent human genome studies have shown that polymorphism of biological clock genes is strongly correlated with the risk of developing emotional and / or addictive disorders such as depression and bipolar disorder, Suggesting the importance of clock molecular mechanisms (Non-Patent Documents 4 and 5).

Dopamine is a catecholamine-based neurotransmitter that can be used as a neurotransmitter in a variety of ways, including motor activity, cognition, emotion, mood, reward, addiction, In particular, the abnormality of the midbrain dopamine system is a major cause of many mental disorders (diseases) and / or neurological diseases (disorders). For example, it is known that abnormal activity of the midbrain dopamine system accounts for a large proportion of symptoms such as emotional disorders and addiction disorders, schizophrenia, attention deficit hyperactivity syndrome (ADHD), Parkinson's disease, Huntington's disease and psychotropic drug dependency (Non-Patent Document 6). The midbrain dopamine system, which shows a common anatomical structure in mammals, is largely divided into two groups: i) a nigrostriatal pathway, which connects to the striatum from the substantia nigra (SN), and a ventral tagmental area (VTA) 2) a mesocortical pathway leading to the mesolimbic pathway and 3) a mesocortical pathway leading to the prefrontal cortex. Dopamine, like other catecholamine neurotransmitters, is synthesized from tyrosine by a series of enzymatic actions, which is the process by which tyrosine is converted to L-DOPA by tyrosine hydroxylase (TH). L-DOPA produced by TH is then rapidly converted to dopamine by DDC (DOPA decarboxylase), stored in the synaptic capsule by VMAT (vesicular monoamine transporter) and secreted into the synapse.

Interestingly, mood and emotional disorders such as Parkinson's disease, Restless leg syndrome, attention deficit hyperactivity disorder (ADHD), and drug addiction And the like are observed. For example, in patients with the disease, disturbance of circadian rhythm is frequently found in sleep disorders including insomnia, body temperature, hormone secretion and blood pressure, and conversely, compulsory sleep- It has been found to be very helpful in relieving symptoms of ADHD patients (Non-Patent Documents 7, 8 and 9). In addition to these phenomena, it has already been known that the activity of the midbrain dopamine neuronal circuit appears periodically (Non-Patent Documents 10, 11 and 12), but the root cause of the periodicity and the linkage with the biological clock molecule network It has not been identified. In recent studies, it has been reported that the TH gene expression is significantly increased in the midbrain of a mutant mouse with a CLOCK gene mutation compared with that of a normal mouse, suggesting that TH in the dopamine synthesis pathway can be linked to the biological clock And failed to elucidate its molecular mechanism (Non-Patent Documents 13 and 14). In addition, mouse studies have shown that impaired expression of Clock genes results in behavioral abnormalities similar to those observed in human emotional disorders. For example, mice with impaired alleles to the Clock gene ( Clock [ Delta ] 19 ) exhibited an increase in activity due to aberrant behavior, complete cocaine sensitivity and midbrain dopamine (Non-Patent Documents 15 and 16). The knockdown of Clock gene mRNA expression in the pectoral region of the pectoral region (VTA) caused similar symptoms to bupropy, characterized by a decrease in anxiety-like behavior but an increase in depressive-like behavior (Non-Patent Document 17). Variations of other clock genes also showed behavioral abnormality. For example, mice deficient in the Bma1 or Per2 genes exhibited an optic behavior, while mice deficient in the Cryptochrome 1 and 2 genes exhibited altered anxiety-like behavior (Non-Patent Documents 18, 19 and 20). These facts suggest that the molecular components of the biological cycle system play an important role in emotion regulation. On the other hand, the polymorphism of the human NR1D1 gene has been associated with the onset of bupropy and the responsiveness to lithium, which is the main treatment for bipolar disorder (Non-Patent Documents 21, 22 and 23).

Therefore, for the prevention and treatment of diverse brain diseases and / or neurological disorders associated with circadian rhythms, the relationship between circadian rhythms and biological clock molecular networks can be identified at the molecular level, identified genes and proteins involved, It is necessary to develop.

Thus, the present inventors have found that the activity of REV-ERBα, which is a nuclear receptor, can be directly used for the treatment of emotional disorders and poisoning diseases, and TH (tyrosine hydroxylase), which is a step for determining the rate of dopamine synthesis through the regulation of REV- The present invention has been accomplished by confirming that it can be used for the prevention and treatment of brain diseases and / or neurological diseases caused by various dopaminergic system disorders including Parkinson's disease.

US Patent No. 5,138,045 US Patent No. 5,218,105 US Patent No. 5,459,255 International Publication No. WO 00/44895 International Publication No. WO 01/36646 International Publication No. WO 99/32619 International Publication No. WO 01/29058 International Publication No. WO 99/07409 International Publication No. WO 00/44914

Ko and Takahashi, 2006, Hum Gen Genet 15: R271. Stratmann and Schibler, 2006, J Biol Rhythms 21: 494. Son et al., 2008, Proc Natl Acad Sci USA 105: 20970. EBenca et al., 2009, Brain Res Rev 62:57. Severino et al., Bipolar Disord 11: 215; McClung, 2007, Pharmacogenomics 8: 1097. Nieoullon, 2002, Prog Neurobiol 67:53. Leibenluft and Suppes, 1999, Am J Psychiatry 156: 1976. Van der Heijden et al., 2005, Chronobiol Int 22: 559. Whitehead et al., 2008, Moving Disord 23: 1137. Aston-Jones et al., 2001, Nat Neurosci 4: 732. Akhisaroglu et al., 2005, Pharmacol Biochem Behav 80: 371. McClung et al., 2005, Proc Natl Acad Sci USA 102: 9377. Lemos et al., 2007, Endocrinology 148: 5811. Roybal et al., 2007, Natl. Acad. Sci. USA 104: 6406. Mukherjee et al., 2010, Biol. Psychiatry 68: 503. Hampp et al., 2008, Curr. Biol. 18: 678. Kondratova et al., 2010, Aging (Albany NY): 285. De Bundel et al., 2013, Front. Behav. Neurosci. 7: 152. Kripke et al., 2009, J. Circadian Rhythms 7: 2. Severino et al., 2009, Bipolar Disord. 11: 215-220. Etain et al., 2011, Neuropsycholpharmacol. 21 Suppl 4: S676-S682. Sambrook et al., 2001, Molecular Cloning. A Laboratory Manual, 3rd ed. Peter B. Kaufma et al., Molecular and Cellular Methods in Biology and Medicine, 102-108, CRCpress. Enzyme Immunoassay, E. T. Maggio, ed., CRC Press, Boca Raton, Florida, 1980. Gaastra, W., Enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology, Vol. 1, Walker, J.M. ed., Humana Press, NJ, 1984. Ed Harlow and David Lane, < / RTI > Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, De Mesmaeker et al., Curr Opin Struct Biol., 5 (3): 343-55,1995. Chopin-Delannoy et al., A specific and unusual nuclear localization signal in the DNA binding domain of the Rev-erb orphan receptors. J. Mol. Endocrinol. 30, 197-211, 2003. Kim et al., Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J. Neurochem. 85, 622-624, 2003. Guez-Barber, D., Fanous, S., Harvey, B.K. Zhang, Y., Lehrmann, E., Becker, K.G., Picciotto, M.R., and Hope, B.T., FACS purification of immunolabeled cell types from adult rat brain. J. Neurosci. Methods 203, 10-18, 2012. Chung et al., Differential adaptive responses to chronic stress in maternally stressed male mice offspring. Endocrinology 146, 3202-3210, 2005. Son et al., Hyperactivity and alteration of the midbrain dopaminergic system in maternally stressed male mice offspring. Biochem. Biophys. Res. Commun. 352, 823-829, 2007. Lee et al., Impairment of fear memory consolidation in maternally stressed male mice offspring: evidence for nongenomic glucocorticoid action on the amygdala. J. Neurosci. 31, 7131-7140, 2011. Chamero et al., Identification of protein pheromones that promotes aggressive behavior. Nature 450, 899-902, 2007. Kojetin et al., Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem. Biol. 6, 131-134, 2011. Woldt et al., Rev-erbamodulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat. Med. 19, 1039-1046, 2013. Suri et al., Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. J. Neurosci. 13, 1280-1291, 1993. Zetterstrom et al., Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248-250, 1997. Yin et al., The orphan nuclear receptor Rev-erbalpha recruits the N-CoR / histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. Mol. Endocrinol. 19, 1452-1459, 2005. Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S. E., Alenghat, T., Liu, X.S., and Lazar, M.A. 2011.

The present invention provides a method for screening novel drug candidates for preventing and / or treating neurological diseases and / or brain diseases caused by dopamine system control abnormalities using a nuclear receptor REV-ERBα protein and a gene encoding the same The purpose is to provide.

It is another object of the present invention to provide a method for screening novel drug candidates which can have a synergistic effect when the drug is co-administered with a therapeutic agent for neurological diseases and / or brain diseases.

The present invention also provides a pharmaceutical composition which is effective for preventing and / or treating neurological diseases and / or brain diseases caused by abnormalities in dopamine system regulation by inhibiting the nuclear receptor REV-ERBα protein and genes encoding the same There is a purpose.

In order to achieve the above object, the present inventors have confirmed the molecular mechanism of the periodic TH gene expression. Specifically, we have identified the competitive transcriptional regulatory mechanism of NURR1, an upregulated transcription factor in dopamine neurons, and REV-ERBα, a key transcriptional repressor in molecular biological clock aids, and their antagonistic actions are mediated by TH gene expression and midbrain dopamine system And that it is a key mechanism of visible daily periodicity. Competitive transcriptional regulation of NURR1 and REV-ERBα is mediated by specific cis -elements, R / N1 and R / N2, present in the TH promoter. These promoter structures and R / N cis- It is also evolutionarily conserved in human TH promoters. The regulatory mechanism is a dopaminergic neuron-specific regulatory mechanism that is different from the competitive transcriptional regulatory mechanism of REV-ERBα and ROR known in the periodic expression control of the Bmal1 gene, The mechanism of action is suggested.

In addition, the present inventors have established animal models. The present inventors conducted seven types of manic, depression, obsessive-compulsive, anxiety and fear-related animal behavior tests on REV-ERB alpha knockout mice, such as tail suspension test, new habitat test and cross- And a similar phenotype appears. The phenotypes of the REV-ERBa knockout mice identified in the present invention are as follows: 1) tail suspension test and forced swimming test: Manic-like traits with depression less than normal were observed; 2) Test for cross-shaped high maze test and response to newness: In terms of motility activity, hyperactivity is observed and anxiety level is significantly lower than that of normal mouse, which can also be regarded as manic-like behavior; 3) Aggression test: A comparison of the aggressiveness of castrated male mice demonstrates abnormal aggressiveness of REV-ERBα knockout mice. High aggressiveness was observed in human mania; 4) Fear-related tests: Despite manic-like behavior and high aggressiveness as described above, the innate fear response to the smell of the predator or the conditioned fear response through conditioned learning is rather higher .

In particular, in REV-ERBa knockout mice, overactivation of the midbrain dopamine neuronal circuit is observed along with dopamine agonism, and the present invention suggests that the abnormal behavior is primarily due to dopamine agonism.

The present invention provides a new control technique for the midbrain dopamine system. Specifically, the example using the agonist of REV-ERBa (GSK4112 (CAS 1216744-19-2)) and the antagonist (SR8278 (ISSN: 1554-8929)) in the present invention showed a new TH gene expression And dopamine synthesis control technology. In vitro experiments using a dopaminergic cell culture, the REV-ERBα controlled drug treatment the R / N1 and R / N2 cis on the TH promoter was the first identified in the present invention - that regulate the transcriptional activity of the TH gene through the element Backed. Specifically, when an antagonist of REV-ERBα was administered to the midbrain of the mouse, it was confirmed that the TH gene was overexpressed not only by local inhibition but also the manic-like behavior was immediately observed. In the mood / emotion control, Demonstrate the functional significance of REV-ERBa, which self-expressed midbrain dopamine neuron cells.

The present invention describes the functional interaction between rev-ERBα, a cyclic nuclear receptor, and NURR1, a key transcription factor of the dopamine system, and identifies the molecular linkage of the midbrain dopamine system, do. In addition, the present invention confirms a mechanism of regulating the cyclic expression of the TH gene, which is a key factor of dopamine synthesis. The present invention also identifies the physiological function of rev-ERBα, which locally expresses midbrain dopaminergic neurons through an animal behavioral model of bipolar disorder and depression.

The term "sample" used in reference to the screening method of the present invention means an unknown candidate used in screening to check whether the amount of gene expression is affected or affects the amount or activity of the protein . Such samples include, but are not limited to, chemicals, nucleotides, antisense-RNA, siRNA (small interference RNA) and natural extracts.

The terms " disorder " and " disease ", as used herein, are understood to have the same meaning.

The terms "fragment", "derivative" and "analog" of a protein or polypeptide as used herein are understood to be proteins or polypeptides having substantially the same function or activity as the protein or polypeptide of the present invention, It is understood that the proteins or polypeptides in the invention include recombinant proteins or polypeptides.

The measurement of the expression level of the gene can be carried out through various methods known in the art. For example, a hybridization reaction using a cDNA microarray (non-patent document 23) or an in situ hybridization reaction (non-patent document 23), northern blotting (non-patent document 24) 23). For example, when the RT-PCR protocol using the SyBR greeen method is used, total RNA is isolated from the cells treated with the sample, and then single strand cDNA is synthesized using primers such as Random Hexamer or oligo-dT and reverse transcriptase . Then, a change in gene expression amount is measured by real-time quantitative PCR using a single-strand cDNA as a template and a gene-specific primer set. The results for real-time PCR are analyzed according to the relative Ct (concentration of target) method, which does not use a standard curve, and are normalized to the control group and expressed as the difference in the number of binding to the control RNA. Gene-specific primer sets are shown in Table 2 below. Table 1 below shows sequences for proteins and genes used in the present invention.

Sequence List Sequence content SEQ ID NO: 1 The human REV-ERB alpha protein amino acid sequence SEQ ID NO: 2 Mouse REV-ERBα protein amino acid sequence SEQ ID NO: 3 The rat REV-ERBα protein amino acid sequence SEQ ID NO: 4 Human TH protein amino acid sequence SEQ ID NO: 5 Mouse TH protein amino acid sequence SEQ ID NO: 6 Rat TH protein amino acid sequence SEQ ID NO: 7 Human REV - ERB alpha gene (mRNA / cDNA) base sequence SEQ ID NO: 8 Mouse REV - ERB α gene (mRNA / cDNA) base sequence SEQ ID NO: 9 The rat REV - ERB α gene (mRNA / cDNA) base sequence SEQ ID NO: 10 Human TH Gene (mRNA / cDNA) base sequence SEQ ID NO: 11 Mouse TH Gene (mRNA / cDNA) base sequence SEQ ID NO: 12 Rat TH Gene (mRNA / cDNA) base sequence SEQ ID NO: 13 The human NURR1 protein amino acid sequence SEQ ID NO: 14 Mouse NURR1 protein amino acid sequence SEQ ID NO: 15 Rat NURR1 protein amino acid sequence SEQ ID NO: 16 The human TH promoter base sequence SEQ ID NO: 17 The mouse TH promoter base sequence SEQ ID NO: 18 The rat rat TH promoter base sequence

Sequence name SEQ ID NO: order  TH up 19 5'-AGT GAT GCC AAG GAC AAG CTC-3 '  TH dn 20 5'-GCT AAT GGC ACT CAG TGC TT-3 '  Rev-erbα up 21 5'-AGG GCA CAA GCA ACA TTA CC-3 '  Rev-erbα dn 22 5'-CAC AGG CGT GCA CTC CAT AG-3 '  Bmal1 up 23 5'-CAA GCA CCT TCC TTC CAA TG-3 '  Bmal1 dn 24 5'-GAT TGC AGT CCA CAC CAC TG-3 '  Per2 up 25 5'-ATG CTC GCC ATC CAC AAGE - 3 '  Per2 dn 26 5'-GCG GAA TCG AAT GGG AGA AT-3 '  Nurr1 up 27 5'-TGA AGA GAG CGG ACA AGG AGA TC-3 '  Nurr1 dn 28 5'-TCT GGA GTT AAG AAA TCG GAG CTG-3 '  TBP up 29 5'-GGG AGA ATC ATG GAC CAG AA-3 '  TBP dn 30 5'-CCG TAA GGC ATC ATT GGA CT-3 '

Changes in the amount of protein can be achieved through a variety of immunoassay methods known in the art. But are not limited to, radioimmunoassays, radioimmunoprecipitation, immunoprecipitation, enzyme-linked immunosorbent assays (ELISAs), capture-ELISAs, inhibition or competition assays, and sandwich assays. Methods for immunological analysis or immunostaining are described in documents (Non-Patent Documents 25, 26, and 27). For example, if the method of the present invention is carried out according to the method radioactive immunoassay, radioactive isotopes (e. G., C ^14, I ^125, P ³² and S ³⁵⁾ The protein labeled with - a specific antibody can be used. When the method of the present invention is carried out by an ELISA method, a specific embodiment of the present invention includes the steps of (i) coating an extract from the treated cells on the surface of a solid substrate (ii) contacting the target protein- (Iii) reacting the result of step (ii) with an enzyme-conjugated secondary antibody, and (iv) measuring the activity of the enzyme. Suitable as said solid substrate are hydrocarbon polymers (e.g., polystyrene and polypropylene), glass, metal or gel, and most preferably microtiter plates. The enzyme bound to the secondary antibody may include an enzyme catalyzing a chromogenic reaction, a fluorescence reaction, a luminescent reaction, or an infrared reaction, but is not limited thereto. For example, an alkaline phosphatase,? -Galactosidase, Radish peroxidase, luciferase, and cytochrome P450. When alkaline phosphatase is used as an enzyme that binds to the secondary antibody, it is preferable to use, as a substrate, bromochloroindole phosphate (BCIP), nitroblue tetrazolium (NBT), naphthol-AS-B1 chromophore and ECF (enhanced chemifluorescence) are used. When horseradish peroxidase is used, chloronaphthol, aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin (bis-N (10-acetyl-3,7-dihydroxyphenoxaphone), TMB (3,3,5,5-tetramethylbenzidine), ABTS < (R) >(2,2'-Azine-di [3-ethylbenzthiazoline sulfonate]) and o-phenylenediamine (OPD). In the ELISA method, the measurement of the final enzyme activity or the measurement of the signal can be performed according to various methods known in the art. If biotin is used as a label, it can be easily detected by streptavidin. When luciferase is used, luciferin can easily detect a signal.

The pharmaceutical composition of the present invention may contain a chemical substance, a nucleotide, an antisense, an siRNA oligonucleotide and a natural product extract as an active ingredient. The pharmaceutical composition or the combined preparation of antifungal compounds of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, A solubilizing agent such as a lubricant, a lubricant, or a flavoring agent may be used. The antifungal drug composition of the present invention may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the active ingredient for administration. Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, as appropriate in the field. The pharmaceutical preparation forms of the pharmaceutical composition of the present invention may be granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, . The pharmaceutical composition of the present invention can be administered orally, intravenously, intramuscularly, intraarterally, intraperitoneally, intrasternally, transdermally, intranasally, by inhalation, topically, rectally, ≪ / RTI > The effective amount of the active ingredient of the pharmaceutical composition of the present invention means the amount required for prevention or treatment of the disease. Accordingly, the present invention is not limited to the particular type of the disease, the severity of the disease, the kind and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the patient's age, body weight, general health status, sex and diet, Rate of administration, duration of treatment, concurrent medication, and the like. For example, in the case of an adult, once or several times a day, the inhibitor of the present invention may be administered at a dose of 0.1 ng / kg to 10 g / kg for a compound once to several times a day, , 0.1 ng / kg to 10 g / kg for protein or antibody, and 0.01 ng / kg to 10 g / kg for antisense oligonucleotides, siRNA, shRNAi and miRNA.

The term "antisense oligonucleotide " in the present invention means DNA or RNA or a derivative thereof containing a nucleic acid sequence complementary to the sequence of a specific mRNA, and binds to a complementary sequence in the mRNA to inhibit translation of the mRNA into a protein . The length of the antisense nucleic acid is 6 to 100 bases, preferably 8 to 60 bases, more preferably 10 to 40 bases. The antisense nucleic acid can be modified at one or more bases, sugar or backbone positions to enhance efficacy (Non-Patent Document 28). The nucleic acid backbone can be modified with phosphorothioate, phosphotriester, methylphosphonate, short chain alkyl, cycloalkyl, short chain heteroatomic, heterocyclic biantennary bond, and the like. In addition, the antisense nucleic acid may comprise one or more substituted sugar moieties. The antisense nucleic acid may comprise a modified base. Modified bases include hypoxanthane, 6-methyladenine, 5-Me pyrimidine (especially 5-methylcytosine), 5-hydroxymethylcytosine (HMC), glycosyl HMC, -Thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N6 (6-aminohexyl) adenine, 2,6-diaminopurine . In addition, the antisense nucleic acid of the present invention may be chemically combined with one or more moieties or conjugates that enhance the activity and cytotoxicity of the antisense nucleic acid. A cholesterol moiety, a cholesteryl moiety, a cholic acid, a thioether, a thiocholesterol, an aliphatic chain, a phospholipid, a polyamine, a polyethylene glycol chain, adamantane acetic acid, a palmityl moiety, octadecylamine, hexylamino- And liposoluble moieties such as Cole sterol moieties. Oligonucleotides containing liposoluble moieties and methods of preparation are well known in the art of the present invention (Patent Documents 1 to 3). The modified nucleic acid may increase the stability to nuclease and increase the binding affinity of the antisense nucleic acid with the target mRNA. In the case of antisense oligonucleotides, they can be synthesized in vitro in a conventional manner and administered in vivo or in vivo to synthesize antisense oligonucleotides. One example of synthesizing antisense oligonucleotides in vitro is using RNA polymerase I. One example of allowing antisense RNA to be synthesized in vivo is to allow the antisense RNA to be transcribed using a vector whose recognition site (MCS) origin is in the opposite direction. Such antisense RNAs are preferably made such that translation stop codons are present in the sequence so that they are not translated into the peptide sequence.

The term "siRNA" in the present invention means a nucleic acid molecule capable of mediating RNA interference or gene silencing (Patent Documents 4 to 9). Since siRNA can inhibit the expression of a target gene, it is provided as an efficient gene knockdown method or as a gene therapy method. siRNAs were first found in plants, insects, fruit flies and parasites, but recently they have been applied to mammalian cell research by developing si / siRNAs (8-10). The siRNA molecule of the present invention may have a structure in which a sense strand (a sequence corresponding to an mRNA sequence) and an antisense strand (a sequence complementary to an mRNA sequence) are located on opposite sides to form a double strand. Also, according to another embodiment, the siRNA molecules of the invention may have a single stranded structure with self-complementary sense and antisense strands. The siRNA is not limited to a complete pair of double-stranded RNA portions that are paired with each other, but is paired by a mismatch (the corresponding base is not complementary), a bulge (no base corresponding to one chain) May be included. The total length is 10 to 100 bases, preferably 15 to 80 bases, more preferably 20 to 70 bases. The siRNA terminal structure is capable of blunt or cohesive termini as long as it can inhibit expression of the gene by the RNAi effect. The sticky end structure can be a 3'-end protruding structure and a 5'-end protruding structure. SiRNA molecules of the invention may have a form in which a short nucleotide sequence (e.g., about 5-15 nt) is inserted between self-complementary sense and antisense strands, in which case the expression of the nucleotide sequence The formed siRNA molecules form a hairpin structure by intramolecular hybridization and form a stem-and-loop structure as a whole. This stem-and-loop structure can be processed in vitro or in vivo to produce active siRNA molecules capable of mediating RNAi.

Meanwhile, in the present invention, the term "shRNA (small hairpin RNA") is used to synthesize oligo DNA ligating 3 to 10 base linkers between the sense of the target gene siRNA sequence and complementary nonsense, Cloning into a vector, or shRNA insertion into a retrovirus, lentivirus and adenovirus, to produce a hairpin shRNA (short hairpin RNA) with a loop, and siRNA . The shRNA shows a relatively long-term RNAi effect as compared to siRNA.

In one embodiment, the present invention provides a recombinant vector comprising (a) a REV-ERBα protein represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 and a TH protein represented by SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 To a sample to be analyzed; (b) measuring the amount or activity of the protein; And (c) confirming that the amount or activity of the REV-ERB [alpha] protein is decreased and the amount or activity of the TH protein is increased; Or REV-ERBa protein is increased and the amount or activity of the TH protein is decreased, it is determined that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease. A method for screening a therapeutic agent for preventing and / or treating an emotional disorder and / or a poisoning disease.

(A) an REV-ERBα protein represented by an amino acid sequence having 90% or more homology with SEQ ID NO: 2 and a TH protein represented by an amino acid sequence having 90% or more homology with SEQ ID NO: 5 Contacting the sample to be analyzed with a cell containing the sample; (b) measuring the amount or activity of the protein; And (c) confirming that the amount or activity of the REV-ERB [alpha] protein is decreased and the amount or activity of the TH protein is increased; Or REV-ERBa protein is increased and the amount or activity of the TH protein is decreased, it is determined that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease. A method for screening a therapeutic agent for preventing and / or treating an emotional disorder and / or a poisoning disease.

In another embodiment, the invention provides a kit comprising (a) an REV-ERBa protein, or an active fragment, derivative or analog thereof; And a TH protein, or an active fragment, derivative or analog thereof, with a sample to be analyzed; (b) measuring the amount or activity of the protein, or an active fragment, derivative or analog thereof; And (c) confirming that the amount or activity of the REV-ERBα protein, or an active fragment, derivative or analog thereof, is decreased and that the amount or activity of the TH protein, or an active fragment, derivative or analog thereof, is increased; Or REV-ERB [alpha] protein, or an active fragment, derivative or analog thereof, and the amount or activity of the TH protein, or an active fragment, derivative or analog thereof, is decreased, And / or a method for screening a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the agent is a preventive and / or therapeutic agent for a poisoning disease.

(A) the REV - ERB alpha gene of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 and the TH gene of SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12, Contacting the sample to be analyzed with a cell containing the sample; (b) measuring the expression level of the gene; And (c) an expression level of the REV - ERB alpha gene is increased and the TH The expression level of the gene is confirmed to be decreased; Or the expression level of the REV-ERB alpha gene is decreased and TH A method for screening for a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease, .

(A) an REV-ERBα gene represented by a nucleotide sequence having 90% or more homology with SEQ ID NO: 8 and a nucleotide sequence having 90% or more homology with SEQ ID NO: 11 Contacting a sample containing the TH gene with a sample to be analyzed; (b) measuring the expression level of the gene; And (c) the expression amount of the REV-ERBα gene is increased and the expression amount of the TH gene is decreased; Or a therapeutic and / or therapeutic agent for an emotional disorder and / or a poisoning disorder when it is confirmed that the expression level of the REV-ERBα gene is decreased and the expression level of the TH gene is increased, Or a method for screening a preventive and / or therapeutic agent for a poisoning disease.

(A) the REV - ERB alpha gene of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 and the TH protein of SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 Contacting the sample to be analyzed with a sample to be analyzed; (b) measuring the expression level of the gene and the amount or activity of the protein; And (c) confirming that the expression amount of the REV-ERBα gene is increased and the amount or activity of the TH protein is decreased; Or REV - ERB alpha gene is decreased and the amount or activity of the TH protein is increased, it is determined that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease , A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease.

In another embodiment, the present invention is directed to a method of producing a recombinant vector comprising (a) contacting a cell comprising a REV-ERBα gene and a TH protein, or an active fragment, derivative or analogue thereof, represented by the nucleotide sequence having 90% or more homology with SEQ ID NO: Contacting the sample to be analyzed; (b) measuring the amount of expression of the gene and the amount or activity of the protein, or an active fragment, derivative or analog thereof; And (c) confirming that the expression level of the REV - ERB alpha gene is increased and the amount or activity of the TH protein, or an active fragment, derivative or analogue thereof is decreased; Or REV-ERBa gene is decreased and the amount or activity of the TH protein, or an active fragment, derivative or analogue thereof, is increased, it is preferable that the sample is used for the prevention and / or prevention of an emotional disorder and / A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of discriminating a therapeutic agent.

(A) the REV-ERBα protein represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, the NURR1 protein represented by SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, Contacting a sample to be analyzed with a cell comprising the R / N1 region and the R / N2 region of the TH promoter represented by SEQ ID NO: 16, SEQ ID NO: 17 or SEQ ID NO: 18; (b) measuring a change in binding force of each of the REV-ERBα protein and the NURR1 protein to the R / N1 and R / N2 regions before and after contacting the sample; And (c) determining whether the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease when the change in the binding force is confirmed. Screening method. Here, the measurement of the change of the binding force of the proteins with respect to each of the R / N1 and R / N2 regions can be performed by measuring a CT (Biological Cycle Time) of a certain period, for example, CT00 to CT12, Lt; / RTI >

In another embodiment, the present invention is directed to a method for the detection of a protein comprising: (a) contacting a sample to be analyzed with a cell comprising an REV-ERBa protein, or an active fragment, derivative or analogue thereof, and an R / N1 region and an R / N2 region of a TH promoter step; (b) measuring the change in the binding force of each of the REV-ERBα protein, or an active fragment, derivative or analogue thereof, and the NURR1 protein to the R / N1 and R / N2 sites before and after contacting the sample; And (c) determining whether the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease when the change in the binding force is confirmed. Screening method. Here, the measurement of the change in the binding force of the proteins for each of the R / N1 and R / N2 sites can be performed in a CT for a certain period of time, for example, CT00 to CT12 or at a certain time point, CT00 and CT12.

In this embodiment, the cells of step (a) are commercially available primary cultured dopamine neurons, induced differentiated dopamine neurons, PC12 cell lines (ATCC available, Catalog No. CRL-1721), dopamine overexpressing immortal cell lines Cath.a Cell line (ATCC available, catalog number CRL-11179, non-patent document 38) or / and MN9D cell line (ATCC available, non-patent document 38).

In another embodiment, the present invention provides an ergative composition for the prevention and / or treatment of an emotional disorder and / or poisoning disorder, comprising an agonist or antagonist of REV-ERBa, wherein the agonist of REV-ERBa is GSK41122 , The antagonist may be SR8278.

In another embodiment, the present invention provides a method for inhibiting neuronal disease, comprising the steps of: (a) administering to a neuron isolated from a patient in need of diagnosis of a dopaminergic neuropathy a neuronal cell, which comprises the R / N1 region and the R / N2 region of the TH promoter of each protein of REV- Measuring the bonding forces at CT00 and CT12; And

(b) determining the binding force measured in step (a) as the R / N1 region and the R / N2 region of the TH promoter of each protein of REV-ERBα and NURR1, measured on CT00 and CT12, And comparing the binding force to each site, the binding force between NURR1 and R / N1 shows an increase in CT12, thereby providing a method for judging the patient as a dopaminergic neuropathy.

In the present invention, brain diseases and neurological disorders (diseases) include emotional disorders and poisoning diseases, and dopaminergic neuropathy. In addition, the emotional disorders and poisoning diseases include various depressive disorders (diseases) and poisoning disorders (diseases) such as depression, manic depression, seasonal mood disorder, attention deficit hyperactivity disorder (ADHD) But is not limited thereto. In addition, dopamine-dependent neurological disorders include, but are not limited to, Parkinson's disease, Huntington's disease, and Restless leg syndrome.

According to the present invention, it is possible to search for an effective candidate substance having a preventive and / or therapeutic effect on a neurological disease caused by abnormalities in dopamine system regulation by regulating the nuclear receptor REV-ERBα protein and a gene encoding the same. In addition, the present invention provides a screening method for a candidate substance which can have a synergistic effect when it is co-administered with a conventional therapeutic agent for neurological diseases. The periodic transcriptional regulatory mechanism of the TH gene identified in the present invention is a novel molecular target of development of therapeutic technology for various cerebellum dopamine-dependent diseases such as depression, depression, seasonal neuropathy, Attention deficit hyperactivity disorder (ADHD) . In addition, the neurophysiological and behavioral characteristics of the cell-based assay model and the REV-ERBa knockout mouse of the present invention can be utilized as an evaluation model for candidate compounds to be subjected to the neurophysiological and behavioral characteristics.

In FIG. 1, (A) shows the daily change of the depression-like behavior, (B) shows the EPM test result, (C) shows the result of the moving habit test, (D) shows the aggression test result, and (E) fear test result.
FIG. 2 is a microarray analysis result of mRNA which is differentially expressed in RKO mouse and wild type mouse.
Figure 3A is a top Bmal1 mRNA, and the lower end of the 3A represents the biocycle vibration of Rev - erb alpha and Per2 mRNA levels.
FIGS. 4A and 4B are the results of analysis of the damage of REV-ERBα, the amount of Nurr1 mRNA expression, and the expression levels of other mRNAs involved in dopaminergic function.
Figures 3C and 5 show the proportion of TH-immunoreactive cells.
FIG. 3E shows the result of immunostaining an adenovirus vector-infected mouse brain section with an anti-TH or anti-Myc labeling antibody, and FIG. 3F shows a result of a despair-like behavior test in a mouse expressing Myc- 3G shows anxiety-like behavior, FIG. 2H shows fear test results, and FIG. 3I shows behavior test results caused by a new one, respectively.
Figures 6A, 6B, 7C and 7D show midbrain dopamine agonistic activity in REV-ERBa deficient mice.
FIGS. 6C and 8 show the effect of REV-ERBα on the electrophysiological characteristics of the midbrain (VMB) of the bipedal side.
Figures 6D to 6E, Figures 9A, 9B, and 9C are results of testing whether dopamine agonistic activity is associated with altered emotion-related behavior in RKO mice.
Figure 10A shows co-expression of biological clock proteins.
FIG. 10B shows changes in TH and Bmal1 mRNA expression due to local inhibition of REV-ERBα by SR8278 microinjection in wild-type and RKO mice.
10C-10G. And Fig. 11 shows the results of observing the behavioral changes of the mice upon microinjection of SR8278.
Figures 12-14 show the results of an antagonistic crosstalk between REV-ERBa and NURR1 in TH gene transcription regulation.
Figure 15 shows that REV-ERB [alpha] and NURR1 are in vivo ( in v / v ) of R / N1 and R / N2.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Materials and Methods

(1) Experimental animals and expression vectors

Male RKO mice (REV-ERB alpha knockout mice) and wild-type mice (10-15 weeks old) were conserved on the C57BL / 6J genetic background. The mice were housed in a temperature-controlled zone at 22-23 ° C in a 12-hour day-night photoperiod (8:00 am lit) environment. After 10 days of cohabitation under photoperiod control, the mice were placed in a continuous cancer environment for 2 days from the time the light was turned off. On day 3, mice were sacrificed at the time indicated by cervical dislocations. All behavioral tests were performed on either 3 or 4 days of continuous cancer. All courses were approved by Seoul National University Laboratory Animals Committee.

Expression vectors have been described in the prior art (Non-Patent Document 29: Chopin-Delannoy et al., 2003, J. Mol. Endocrinol. 30, 197-211; Non-Patent Document 30: Kim et al., 2003, J. Neurochem. 622-634; Non-Patent Document 3: Son et al., 2008, Proc. Natl. Acad. Sci. USA 105, 20970-20975). The rat 5.2Kb TH promoter and its sequential deletion derivatives were prepared as detailed in a previous paper (Non-Patent Document 30: Kim et al., 2003, J. Neurochem. 85, 622-634). (From position 2491 to position 9 from the translation start position), the mouse TH promoter (-2306 to -1 from the translation start position) and the human TH promoter (from the translation start position to the wild-type and position-specifically mutated 2.4 Kb rat TH promoter -2523 to +76) were prepared using PCR.

(2) Drug used and route of administration

HALO (0.2 mg / kg; Sigma Aldrich) or AMPT (100 mg / kg; Sigma-Aldrich) was intraperitoneally injected into the mice 1-2 hours before the test. SR8278 was intravenously injected (ICV) at 64 ug per mouse 6 hours before starting electrophysiological recording. For behavioral studies and gene expression analysis, SR8278 was injected directly into the midbrain (VMB) or periventricular gray matter (PVG) 4 hours before the experiment.

(3) Contents and method of action research

All behavioral tests were performed at designated times under dim red lighting.

(4) RNA  And protein analysis

Tissues were rapidly harvested and frozen in liquid nitrogen. Total RNA was isolated by single step acid anilinium thiocyanate - phenol chloroform method. Samples for immunoblot analysis were prepared by homogenizing the tissues in SDS lysis buffer.

(5) FACS  analysis

To determine the number of populations of neuronal cells activated by dopamine, flow cytometry was performed according to the method described in the existing paper (Non-Patent Document 31: Guez-Barber et al., 2012, J. Neurosci. Methods 203, 10-18) Respectively. Bovine midbrain tissue was rapidly cut from a 2 mm thick brain section to an ice-cooled brain matrix (two mouse analyzes) and the cut tissue was transferred into ice-cold Hibernate A solution (manufacturer: Invitrogen) Accutase (manufacturer: Millipore) and analyzed by flow cytometry.

(6) dopamine DA ) Measure

Over-fusion and measurement of dopamine and metabolites in vitro were carried out according to the methods described in the existing paper (Non-Patent Document 31: Geldenhuys et al., 2009, Eur. J. Pharmacol. 619, 38-43). For static culture, the freshly cut filament tissue was equilibrated for 60 minutes and the eluted samples were collected 3 times at 20 minute intervals. To measure extracellular levels of dopamine and dopamine metabolites in vivo, a microdialysis (CMA microdialysis) probe with a 1 mm membrane length was inserted into the anteriorlybone line. The probe was perfused with sterile artificial cerebrospinal fluid at a rate of 1.5 μl / min. Microdialysates were collected at 2-hour intervals after 2 hours before perfusion. Dopamine (DA), DOPAC and HVA were analyzed using reversed phase high performance liquid chromatography with electrochemical detection.

(7) Electrophysiological record

A microdrive arrangement (i.e., a hyperdrive) consisting of 8 to 9 vacuum tubes and one reference electrode was used for electrophysiological recording in the freely-moving mouse's ventral side (VTA). Neuronal spiking data were amplified and quantified using a digital Lynx data acquisition system (Neuralynx).

(8) Cell culture

Cell culture material was purchased from Invitrogen. CATH.a cells were cultured in RPMI 1640 medium supplemented with 4 mM glutamine, 1 mM sodium pyruvate, 100 U / ml penicillin / streptomycin and 10% fetal bovine serum. Transfection and luciferase-reporter experiments were performed.

(9) ChiP  Analysis experiment

ChiP assays were performed using a commercial kit (manufacturer: Thermo Fisher Scientific).

(10) Statistical analysis

The differences between the experimental groups were measured using the Student's t-test (t-test) or the one-way ANOVA (Newman-Keuls comparison). The migration and nerve cell Ignition rates were calculated by repeatedly measuring by subjecting it to peroxidation followed by analysis of variance (ANOVA). Statistical significance was set at p <0.05.

Example

Related to abnormal feelings REV - ERB Phenotype of α-deficient mice

A despair-based tail-hanging test (TST) and a forced swimming test (FST) as tests for depressive-like behavior are described in the existing paper (Non-Patent Document 15: Roybal et al., 2007, Proc. Natl. Acad. Sci. USA 104, 6406-6411; Non-Patent Document 17: Hampp et al., 2008, Curr. Biol. 18, 678-683). For TST, each mouse was tacked in a white box (36.5 x 30.5 x 30.5 cm) for 6 minutes. The mouse was considered unstable when the anxiety and escape attempts were stopped. In the FST test, the mice were left in a clear beaker (10 cm in diameter) containing 15 cm of water (21 to 25 캜) for 6 minutes. The immobility, defined as no intentional body or leg motion, was calculated as a percentage of the time spent not moving for the last 4 minutes. The anxiety behavior test was conducted as described in the existing paper (Non-Patent Document 32: Chung et al., 2005, Endocrinology 146, 3202-3210). The labyrinth consisted of two open arms with two 20 cm high walls and two closed arms. The device was installed 50 cm above the ground. Each mouse was placed in the center of the device for viewing the open arms for 10 minutes. The frequency and duration of cancer access were recorded. Entry was defined as moving the mouse 4 feet toward the cancer. The percentage of time spent in open cancer was calculated. The motility habituation test was conducted by partially modifying the method described in the existing paper (Non-Patent Document 33: Son et al., 2007, Biochem. Biophys. Res. Commun. 352, 823-829). The mice were transferred one by two to a safety glass box (217 x 268 x 104 mm) with litter for 2 hours. Mouse behavior was recorded using a high-level video camera connected to a computer equipped with tracking software (Ethovision 3.1, Noldus). The fear response test was performed according to the method described in the existing paper (Non-Patent Document 34: Lee et al., 2011, J. Neurosci. 31, 7131-7140). The mice were placed in a chamber with a beaker containing 30 l of trimethylthiazoline (TMT, PheroTech). Behavior for instinctive fear in response to predator odor was measured for 10 minutes and calculated as the percentage of time during the last 4 minutes of fear showing. Aggression was carried out by partially modifying the method described in the existing paper (Non-Patent Document 35: Chamero et al., 2007, Nature 450, 899-902). Male mice were isolated for one week prior to testing and male BALB / C intruder mice (8-9 weeks old) castrated were placed in cages of isolated male mice for 5 minutes. The number of aggressive contact behaviors such as tail bending, bite, tracking and cornering were measured.

In the desensitization-based tail suspension test (TST) and the forced swimming test, the wild-type (WT) mice were more subjective than the subjective dawn (CT) , Biochemical cycle time 08 to 12 hours; CT08-12) (Fig. 1A). RKO mice, on the other hand, did not exhibit any of the behavioral changes described above and were less likely to experience depression-like behavior after sunset. Wild-type mice showed more anxiety-like behavior within EPM after sunset, but RKO mice showed similar degree of anxiety regardless of time of day (Figure 1B). Wild-type mice exhibited a faster habituation response to the new environment (Fig. 1C, left) and shifted a short distance after sunset (Fig. 1C right) than before sunrise. On the other hand, RKO mice did not show periodic changes in movement. Male RKO mice showed stronger aggressiveness than wild-type mice. Less than 20% of the wild-type mice attacked castrated male chip particles, but more than 50% of RKO mice attacked the intruder (FIG. 1D). Daily changes in aggressiveness were not observed in wild type or RKO mice.

In the fear test, the RKO mice experienced greater fear when exposed to the predator feces odor (trimethylthiazoline, FIG. 1E) after sunset, and the instinctive response to fear was more rapid in RKO mice than in wild type mice Respectively. These results suggest that RKO mice exhibit emotional instability, imitation, and at least some symptoms similar to those observed in patients with human bipolar disorder.

About emotional behavior Tyrosine  Hydrolytic enzymes ( TH )

Considering the transcriptional inhibitory activity of REV-ERBa, the present inventors analyzed expression of allele-genomic genes in the bovine midbrain rich in dopaminergic neurons. Microarray analysis confirmed some mRNAs differentially expressed between RKO mice and wild type mice (Fig. 2). Expression levels of TH mRNA encoding the enzymes of the rate determining step for dopamine biosynthesis were higher in RKO mice than in wild type mice. The intracellular expression patterns of dopamine in wild-type mice were significantly higher than those of Bmal1 (Fig. 3A, top). TH and Bmal1 mRNA level was increased in the nighttime, which Rev - erb α and differed from the living cycle of vibration Per2 mRNA levels (Fig. 3a, bottom). The amount of expression of Nurrl mRNA, the major transcriptional activator of TH and other dopamine related genes, and the expression levels of other mRNA species related to dopamine function were less affected by the loss of cyclic or functional REV-ERBa (Figures 4a and 4b) .

Immunohistochemistry showed that TH protein expression was similar to that of the substantia nigra (SN) of the wild type mouse and the similar biocycle changes in the dorsal side of the pterygium. Quantitative analysis based on FACS supported this and showed that the proportion of TH-immunoreactive cells associated with NeuN-positive neuronal populations was higher in CT00 than in CT12 (FIG. 3C and FIG. 5). These periodic changes did not occur due to abnormally high TH expression in both the middle cerebral blood vessels and the pectoral papillae in the RKO mice. These results suggest that REV-ERBα regulates TH expression by inhibitory mechanisms. To test whether altered TH expression causes a change in emotion-related behavior, the present inventors have shown that human TH (hTH-Myc) labeled at the C-terminus under the control of the CMV promoter is continuously expressed as an adenovirus (AAV) vector system . Immunostaining of AAV-infected mouse brain sections with anti-TH or anti-Myc-labeled antibodies showed that approximately one-third of the TH-positive cells in the dorsal side of the papillary papillary region coexpressed Myc labeled TH (Fig. 3 E; 41.11 ± 5.14%, n = 6, calculated from 3-4 sections randomly selected for each mouse within ± 0.5 mm from the injection site). As expected, the transformed cells were mostly observed in the abdominal part (VTA) and almost not in the middle cerebral blood (SN).

We also performed behavioral tests on hTH-Myc expressing mice and GFP transfected control mice in CT08-12. Similar to RKO mice, mice expressing Myc-labeled hTH decreased despair-like behavior ( FIG. 3 F), anxiety-like behavior ( FIG. 3 G) and instinctive fear ( FIG . However, the motility habituation response to the new environment was equivalent in both hTH-expressing mice and control mice ( Fig. 3 I), suggesting that the neurons into which hTH is introduced are concentrated in the mesenchymal rather than middle cerebral blood, Neurobiol. 67, 53-83), although dopamine-activated neurons are more likely to be associated with motor function (Nieoullon, 2002, Prog. Neurobiol. These results suggest that irregular and increased TH expression is related to the manic phenotype of RKO mice.

REV - ERB midbrain dopamine in alpha deficient mice Operability  activation

We compared the central nervous system dopamine agonistic activity between RKO mice and wild type mice. The present inventors have examined natural dopamine release from striations including ex vivo static cultures (CPu, caudate putamen) and lateral nuclei (NAc, nucleus accumbens). Wild striatal cultures in CT00 release more dopamine than cultures in CT12, but such changes do not occur in RKO mouse tissue due to increased dopamine release at CT12 (FIG. 6 a). Similar to striatal dopamine content and similar patterns of increased metabolism, these results suggest that RKO mice exhibit changes in dopamine production. Further, extracellular levels of dopamine and dopamine metabolites were measured in living mice via microdialysis, and a greater amount was measured in the lateral nucleus of RKO mice than in wild-type mice (FIG. 6B and FIGS. 7C and 7D). REV-ERBa has been shown to have a significant effect on the electrophysiological characteristics of the ventral midbrain (VMB) (Figs. 6C and 8), with an increase in extracellular dopamine levels. The electrophysiological activity in the dorsal side of the parietal region was determined by rapid inhibition of REV-ERBα by intracerebral administration of SR8278 (Non-Patent Document 36: Kojetin et al., 2011), a potent REV-ERBa antagonist, (FIG. 6C) in mice that were free to move relative to the mice injected with the control (FIG. 6C), suggesting that this was due to an increase in the rate of rapid spiking neurons (Fig. 8). This increase in dopamine synthesis and secretion in the ventral midbrain (VMB) showed hyperactivity of the dopamine system in RKO mice.

The present inventors have analyzed whether increased dopaminergic activity is associated with altered emotion-related behavior in RKO mice. The overall administration of the dopamine receptor antagonist haloperidol (HALO) or the TH inhibitor alpha-methyl-para-tyrosine (AMPT), particularly during late night time (CT20-24) , Which weakened daily variation of behavior related to emotions. More importantly, the abnormal behavior of RKO mice observed after sunset (dusk) was alleviated to a level similar to that observed in wild-type mice after administration of either of the inhibitors (Figures 6D-6E). In addition, both inhibitors reduced the mobility of wild-type mice at night and reduced the hyperactivity of RKO mice at daytime (FIGS. 9A and 9B), completely inhibiting the aggressiveness of wild-type and RKO mice (results not shown ). The present inventors could not completely exclude the possibility that the altered locomotor activity would affect the behavioral response, since such inhibitors increase the increased rigidity of the wild-type mice tested after sunset (Figure 9C). These results, along with hTH-Myc expression (Figure 3E-I), suggest that certain mechanisms required for excessive dopaminergic activity during sleep may be the basis for reduced depression and anxiety-like behavior in RKO mice.

And Bather  Midbrain VMB ) My REV - ERB Inhibition of alpha activity

Since most TH-immunoreactive dopaminergic neurons co-express basic biological clock proteins such as REV-ERBa, BMAL1 and PER1 (Fig. 10A), we found that locally expressed REV-ERBa in the midbrain of the biceps modulates TH expression And affect emotional regulation. Local inhibition of REV-ERBα by SR8278 microinjection in wild-type mouse bovine midbrain increased TH and Bmal1 mRNA expression in CT12 compared to RKO mice, but SR8278 did not alter TH expression in RKO mice (FIG. 10B), and the possibility that REV-ERBα in the midbrain of bovine brain directly regulates TH mRNA expression was increased. Microinjection of SR8278 into the midbrain of the biceps rather than the control zone (ie, periventricular gray, PVG) caused abnormal behaviors similar to those seen with RKO mice. SR8278 reduced despair-like immobility in wild-type mice to levels similar to those in RKO mice during the daytime (CT08-12 or Zitburgh time 08-12, ZT08-12), but activity time (CT or ZT20-24, 10C) had little effect on despair-like behavior. In addition, mice injected with SR8278 showed a decrease in anxiety-like behavior (Fig. 10D and Fig. 11) after sunset, and instinctive fear increased (Fig. 10E) (Fig. 10F).

When exposed to the new situation, SR8278-injected wild-type mice exhibited more overactivity than RKO mice under constant arm conditions and shifted 2 to 3 times longer distance than wild-type mice in CT20-24, whereas RKO mice And the total distance traveled by wild-type mice was even at dawn (Fig. 1C). In this regard, it should be noted that RKO mice exhibit reduced motor activity and impaired mitochondrial content and oxidative function of skeletal muscle (Woldt et al., 2013). Since SR8278 microinjection into the midbrain of the biceps does not affect the muscle activity of REV-ERBα, it is believed that more active movement can be observed. In addition, mice injected with SR8278 showed excessive activity in response to a new situation during the cancer phase of the LD cycle. But. The mice were less active during the daytime, even in tests under dim red lighting. Considering that mice injected with SR8278 migrate farther than the control mice in ZT08-12 under the same illumination conditions, exposure to light before testing is thought to inhibit transient activity temporarily.

These results suggest that REV-ERBα activity in the midbrain of the biceps plays a major role in emotion regulation and TH mRNA expression.

TH  In gene transcription regulation REV - ERB alpha and NURR1  Between Antagonistic  Crosstalk ( crosstalk )

Since the local REV-ERBα activity in the bovine midbrain controls TH mRNA expression, the present inventors have tested using a dopaminergic cell line in which REV-ERBα acts on the TH gene promoter and directly controls the TH gene transcription (CATH.a; Non-Patent Document 38: Suri et al., 1993). Sequence analysis revealed a nuclear receptor (ROR) reactive component (RRE) associated with several potential REV-ERBs / retinoic acid receptors as well as the E-box component, which are located within ~ 5 Kb upstream of the encoded sequence Was recognized by the CLOCK: BMAL1 dimer in the rat TH promoter region. Some of these factors are well conserved in rats, mice, and humans (Figure 12A). REV-ERB alpha inhibited the luciferase transporter activity (r TH -LUC) by the rat TH promoter, but ROR alpha and CLOCK: BMAL1 dimers had little effect (Fig. 12B). Interestingly, the potential RRE in the TH promoter is recognized by the nuclear receptor NURR1 (NBRE: NGFI-B responsive component; Fig. 13A) and overlaps with the previously identified cis- elements because of the proper development of dopaminergic neurons (Non-Patent Document 39: Zetterstrom et al., 1997; Non-Patent Document 30: Kim et al., 2003). REV-ERBa antagonizes the NURR1 mediated activation of the TH promoter, while the Bmal1 promoter is hardly affected by NURR1 overexpression (Fig. 12B). This antagonistic crosstalk between REV-ERBa and NURR1 was also shown for reporters by the mouse and human TH promoters (m TH -LUC and h TH -LUC, respectively), indicating evolutionary conservation ).

Sequentially deleted TH promoters and the site-specifically deleted 2.4Kb promoter were identified as two potential RRE / NBRE (designated R / N1 and R / N2, respectively) in the region between 2.6 Kb and 1.2 Kb of the TH promoter ) Act on the major cis-active sites of these novel crosstalk (Figs. 13A-B and Fig. 14). Regulation of the endogenous REV-ERBa activity by treatment with the REV-ERBa agonist GSK4112 or antagonist SR8278 can be accomplished using R / N1 (1023-1224 in SEQ ID NO: 16, 766-777 in SEQ ID NO: 17, or 921-932 in SEQ ID NO: 18) Dependent manner on R / N2 (150-161 in SEQ ID NO: 16, 154-165 in SEQ ID NO: 17, or 327-338 in SEQ ID NO: 18) (Fig. 13C). Likewise, ChIP experiments demonstrated that REV-ERBα and NURR1 directly bound to R / N1 and R / N2 did not recognize the RRE components on adjacent NBRE or Bmal promoters on the TH promoter, respectively Respectively.

Due to this fact, the present inventors have raised questions about how these nuclear receptors interact at the recognition site on the TH promoter.

We have found that the increased amount of GFP-labeled REV-ERBa inhibits the TH promoter activation in a dose-dependent manner caused by FLAG-conjugated NURR1. Thus, quantitative ChIP testing following the expression of GFP-REV-ERBα and Flag-NURR1 at different molar ratios indicated that these nuclear receptors compete to recognize R / N1 and R / N2 components (Figure 13F) . Thus, the present inventors speculated that target-dependent antagonistic crosstalk between the two nuclear receptors would be the basis for TH expression in the biological clock.

TH  In the promoter Histone On acetylation  About REV - ERB alpha-dependent regulation

Next the present inventors in (in the REV-ERBα and NURR1 vivo RTI ID = 0.0 > R / N1 &lt; / RTI &gt; and R / N2 in vivo . The binding of REV-ERBα to R / N1 and R / N2 in wild-type bovine midbrain was stronger in CT12 than in CT00 (binding force of REV-ERBα and R / N1 and R / N2: CT12> CT00) The binding strength of NURR1 to / N1 and R / N2 was observed to be stronger than that of CT12 (binding strength of NURR1 and R / N1 and R / N2: CT00> CT12) than CT12 (Fig. 15A). The day shift of REV-ERBα binding appeared to be more active for adjacent R / N1 components, while NURR1 bound more effectively than at the R / N2 position. In CT12, the binding of NURR1 to the R / N component was greater than in RKO mice (Figure 15A) and the NURR1-R / N1 binding was more potent in RKO mice at CT12 than in wild type mice at CT00 (See Tables 3 to 5 below).

Combined object Strength of bond strength R / N1 and R / N2 REV-ERBα CT12 > CT00 NURR1 CT00 CT12

Combined object Time Strength of bond strength R / N1 and R / N2 NURR1 CT12 RKO > Wild type

Combined object Strength of bond strength R / N1 NURR1 RKO (at CT12) > Wild type (at CT00)

These results indicate that target-dependent antagonistic crosstalk between these nuclear receptors can occur through competitive binding to in vivo R / N components. REV-ERBa inhibits the transcription of a target gene by recruiting a histone deacetylase 3 (HDAC3) complex as a promoter region (Non-Patent Document 40: Yin et al., 2005; Non-Patent Document 41: Feng et al., 2011). Thus, we have confirmed the induction of HDAC3 into the TH promoter region and thereby the histone acetylation status. The induction of HDAC3 to the R / N1 region was caused by the biological clock rhythm in the midbrain of the midbrain of wild type mice. However, this rhythm did not appear in the midbrain of RKO biceps (Fig. 15B). On the other hand, the daily change in HDAC3 induction to the more remote R / N2 position was scarcely evident, as shown in Figure 16A, in which R / N2 is less efficiently conjugated to REV-ERBa than the R / N1 site And that it is occupied. Acetylation (H3-K9) of lysine 9 of histone H3 showed the rhythm of the biocycle in all three TH promoter regions tested in an REV-ERBa-dependent manner. The biocyclic pattern of histone acetylation is very similar to the TH mRNA expression pattern, but in contrast to the results of REV-ERBα or HDAC3. H3-K9 acetylation and induction of HDAC3 into the adjacent promoter region (PROX) caused a daily oscillation similar to that found in the region containing R / N1.

These results suggest that REV-ERBα regulates TH gene expression by inducing the HDAC3 complex and negatively regulates histone acetylation, which inhibits the transcriptional activation of the TH gene promoter.

<110> Seoul National University          Korea University <120> Use of REV-ERBalpha for treating dopamine-dependent disorders <130> IPDC52701 <160> 30 <170> Kopatentin 2.0 <210> 1 <211> 614 <212> PRT <213> human <400> 1 Met Thr Thr Leu Asp Ser Asn Asn Asn Thr Gly Gly Val Ile Thr Tyr   1 5 10 15 Ile Gly Ser Ser Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser              20 25 30 Tyr Ser Asp Asn Ser Asn Gly Ser Phe Gln Ser Leu Thr Gln Gly Cys          35 40 45 Pro Thr Tyr Phe Pro Pro Ser Pro Thr Gly Ser Leu Thr Gln Asp Pro      50 55 60 Ala Arg Ser Phe Gly Ser Ile Pro Pro Ser Leu Ser Asp Asp Gly Ser  65 70 75 80 Pro Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Phe Tyr Asn                  85 90 95 Gly Ser Pro Pro Gly Ser Leu Gln Val Ala Met Glu Asp Ser Ser Arg             100 105 110 Val Ser Ser Ser Ser Thr Ser Asn Ile Thr Lys Leu Asn Gly Met         115 120 125 Val Leu Leu Cys Lys Val Cys Gly Asp Val Ala Ser Gly Phe His Tyr     130 135 140 Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile 145 150 155 160 Gln Gln Asn Ile Gln Tyr Lys Arg Cys Leu Lys Asn Glu Asn Cys Ser                 165 170 175 Ile Val Arg Ile Asn Arg Asn Arg Cys Gln Gln Cys Arg Phe Lys Lys             180 185 190 Cys Leu Ser Val Gly Met Ser Arg Asp Ala Val Arg Phe Gly Arg Ile         195 200 205 Pro Lys Arg Glu Lys Gln Arg Met Leu Ala Glu Met Gln Ser Ala Met     210 215 220 Asn Leu Ala Asn Asn Gln Leu Ser Ser Gln Cys Pro Leu Glu Thr Ser 225 230 235 240 Pro Thr Gln His Pro Thr Pro Gly Pro Met Gly Pro Ser Pro Pro Pro                 245 250 255 Ala Pro Val Ser Pro Leu Val Gly Phe Ser Gln Phe Pro Gln Gln             260 265 270 Leu Thr Pro Pro Arg Ser Ser Pro Glu Pro Thr Val Glu Asp Val         275 280 285 Ile Ser Gln Val Ala Arg Ala His Arg Glu Ile Phe Thr Tyr Ala His     290 295 300 Asp Lys Leu Gly Ser Ser Pro Gly Asn Phe Asn Ala Asn His Ala Ser 305 310 315 320 Gly Ser Pro Ala Thr Thr Pro His Arg Trp Glu Asn Gln Gly Cys                 325 330 335 Pro Pro Ala Pro Asn Asp Asn Asn Thr Leu Ala Ala Gln Arg His Asn             340 345 350 Glu Ala Leu Asn Gly Leu Arg Gln Ala Pro Ser Ser Tyr Pro Pro Thr         355 360 365 Trp Pro Pro Gly Pro Ala His His Ser Cys His Gln Ser Asn Ser Asn     370 375 380 Gly His Arg Leu Cys Pro Thr His Val Tyr Ala Ala Pro Glu Gly Lys 385 390 395 400 Ala Pro Ala Asn Ser Pro Arg Gln Gly Asn Ser Lys Asn Val Leu Leu                 405 410 415 Ala Cys Pro Met Asn Met Tyr Pro His Gly Arg Ser Gly Arg Thr Val             420 425 430 Gln Glu Ile Trp Glu Asp Phe Ser Met Ser Phe Thr Pro Ala Val Arg         435 440 445 Glu Val Glu Phe Ala Lys His Ile Pro Gly Phe Arg Asp Leu Ser     450 455 460 Gln His Asp Gln Val Thr Leu Leu Lys Ala Gly Thr Phe Glu Val Leu 465 470 475 480 Met Val Arg Phe Ala Ser Leu Phe Asn Val Lys Asp Gln Thr Val Met                 485 490 495 Phe Leu Ser Arg Thr Thr Ser Leu Gln Glu Leu Gly Ala Met Gly             500 505 510 Met Gly Asp Leu Leu Ser Ala Met Phe Asp Phe Ser Glu Lys Leu Asn         515 520 525 Ser Leu Ala Leu Thr Glu Glu Glu Leu Gly Leu Phe Thr Ala Val Val     530 535 540 Leu Val Ser Ala Asp Arg Ser Gly Met Glu Asn Ser Ala Ser Val Glu 545 550 555 560 Gln Leu Gln Glu Thr Leu Leu Arg Ala Leu Arg Ala Leu Val Leu Lys                 565 570 575 Asn Arg Pro Leu Glu Thr Ser Arg Phe Thr Lys Leu Leu Leu Lys Leu             580 585 590 Pro Asp Leu Arg Thr Leu Asn Asn Met His Ser Glu Lys Leu Leu Ser         595 600 605 Phe Arg Val Asp Ala Gln     610 <210> 2 <211> 615 <212> PRT <213> mouse <400> 2 Met Thr Thr Leu Asp Ser Asn Asn Asn Thr Gly Gly Val Ile Thr Tyr   1 5 10 15 Ile Gly Ser Ser Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser              20 25 30 Tyr Ser Asp Ser Ser Asn Gly Ser Phe Gln Ser Leu Thr Gln Gly Cys          35 40 45 Pro Thr Tyr Phe Pro Pro Ser Pro Thr Gly Ser Leu Thr Gln Asp Pro      50 55 60 Ala Arg Ser Phe Gly Ser Ala Pro Pro Ser Leu Ser Asp Asp Ser Ser  65 70 75 80 Pro Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Phe Tyr                  85 90 95 Asn Gly Ser Pro Pro Gly Ser Leu Gln Val Ala Met Glu Asp Ser Ser             100 105 110 Arg Val Ser Ser Ser Lys Gly Thr Ser Asn Ile Thr Lys Leu Asn Gly         115 120 125 Met Val Leu Leu Cys Lys Val Cys Gly Asp Val Ala Ser Gly Phe His     130 135 140 Tyr Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser 145 150 155 160 Ile Gln Gln Asn Ile Gln Tyr Lys Arg Cys Leu Lys Asn Glu Asn Cys                 165 170 175 Ser Ile Val Arg Ile Asn Arg Asn Arg Cys Gln Gln Cys Arg Phe Lys             180 185 190 Lys Cys Leu Ser Val Gly Met Ser Arg Asp Ala Val Arg Phe Gly Arg         195 200 205 Ile Pro Lys Arg Glu Lys Gln Arg Met Leu Ala Glu Met Gln Ser Ala     210 215 220 Met Asn Leu Ala Asn Asn Gln Leu Ser Ser Leu Cys Pro Leu Glu Thr 225 230 235 240 Ser Pro Thr Pro His Pro Thr Ser Gly Ser Met Gly Pro Ser Pro Pro                 245 250 255 Pro Ala Pro Ala Pro Thr Pro Leu Val Gly Phe Ser Gln Phe Pro Gln             260 265 270 Gln Leu Thr Pro Pro Arg Ser Ser Pro Glu Pro Thr Met Glu Asp         275 280 285 Val Ile Ser Gln Val Ala Arg Ala His Arg Glu Ile Phe Thr Tyr Ala     290 295 300 His Asp Lys Leu Gly Thr Ser Pro Gly Asn Phe Asn Ala Asn His Ala 305 310 315 320 Ser Gly Ser Ser Ala Thr Thr Pro His Arg Trp Glu Ser Gln Gly                 325 330 335 Cys Pro Ser Ala Pro Asn Asp Asn Asn Leu Leu Ala Ala Gln Arg His             340 345 350 Asn Glu Ala Leu Asn Gly Leu Arg Gln Gly Pro Ser Ser Tyr Pro Pro         355 360 365 Thr Trp Pro Ser Gly Pro Thr His His Ser Cys His Gln Pro Asn Ser     370 375 380 Asn Gly His Arg Leu Cys Pro Thr His Val Tyr Ser Ala Pro Glu Gly 385 390 395 400 Glu Ala Pro Ala Asn Ser Leu Arg Gln Gly Asn Thr Lys Asn Val Leu                 405 410 415 Leu Ala Cys Pro Met Met Met Tyr Pro His Gly Arg Ser Gly Arg Thr             420 425 430 Val Gln Glu Ile Trp Glu Asp Phe Ser Met Ser Phe Thr Pro Ala Val         435 440 445 Arg Glu Val Val Glu Phe Ala Lys His Ile Pro Gly Phe Arg Asp Leu     450 455 460 Ser Gln His Asp Gln Val Thr Leu Leu Lys Ala Gly Thr Phe Glu Val 465 470 475 480 Leu Met Val Arg Phe Ala Ser Leu Phe Asn Val Lys Asp Gln Thr Val                 485 490 495 Met Phe Leu Ser Arg Thr Thr Tyr Ser Leu Gln Glu Leu Gly Ala Met             500 505 510 Gly Met Gly Asp Leu Leu Asn Ala Met Phe Asp Phe Ser Glu Lys Leu         515 520 525 Asn Ser Leu Ala Leu Thr Glu Glu Glu Leu Gly Leu Phe Thr Ala Val     530 535 540 Val Leu Val Ser Ala Asp Arg Ser Gly Met Glu Asn Ser Ala Ser Val 545 550 555 560 Glu Gln Leu Gln Glu Thr Leu Leu Arg Ala Leu Arg Ala Leu Val Leu                 565 570 575 Lys Asn Arg Pro Ser Glu Thr Ser Arg Phe Thr Lys Leu Leu Leu Lys             580 585 590 Leu Pro Asp Leu Arg Thr Leu Asn Asn Met His Ser Glu Lys Leu Leu         595 600 605 Ser Phe Arg Val Asp Ala Gln     610 615 <210> 3 <211> 615 <212> PRT <213> rat <400> 3 Met Thr Thr Leu Asp Ser Asn Asn Asn Thr Gly Gly Val Ile Thr Tyr   1 5 10 15 Ile Gly Ser Ser Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser              20 25 30 Tyr Ser Asp Ser Ser Asn Gly Ser Phe Gln Ser Leu Thr Gln Gly Cys          35 40 45 Pro Thr Tyr Phe Pro Pro Ser Pro Thr Gly Ser Leu Thr Gln Asp Pro      50 55 60 Ala Arg Ser Phe Gly Thr Val Pro Ser Leu Ser Asp Asp Ser Ser  65 70 75 80 Pro Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Phe Tyr                  85 90 95 Asn Gly Ser Pro Pro Gly Ser Leu Gln Val Ala Met Glu Asp Ser Ser             100 105 110 Arg Val Ser Ser Ser Lys Gly Thr Ser Asn Ile Thr Lys Leu Asn Gly         115 120 125 Met Val Leu Leu Cys Lys Val Cys Gly Asp Val Ala Ser Gly Phe His     130 135 140 Tyr Gly Val His Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser 145 150 155 160 Ile Gln Gln Asn Ile Gln Tyr Lys Arg Cys Leu Lys Asn Glu Asn Cys                 165 170 175 Ser Ile Val Arg Ile Asn Arg Asn Arg Cys Gln Gln Cys Arg Phe Lys             180 185 190 Lys Cys Leu Ser Val Gly Met Ser Arg Asp Ala Val Arg Phe Gly Arg         195 200 205 Ile Pro Lys Arg Glu Lys Gln Arg Met Leu Ala Glu Met Gln Asn Ala     210 215 220 Met Asn Leu Ala Asn Asn Gln Leu Ser Ser Leu Cys Pro Leu Glu Thr 225 230 235 240 Ser Pro Ala Pro His Pro Thr Ser Gly Ser Val Gly Pro Ser Pro Pro                 245 250 255 Pro Ala Pro Ala Pro Thr Pro Leu Val Gly Phe Ser Gln Phe Pro Gln             260 265 270 Gln Leu Thr Pro Pro Arg Ser Ser Pro Glu Pro Thr Val Glu Asp         275 280 285 Val Ile Ser Gln Val Ala Arg Ala His Arg Glu Ile Phe Thr Tyr Ala     290 295 300 His Asp Lys Leu Gly Thr Ser Pro Gly Asn Phe Asn Ala Asn His Ala 305 310 315 320 Ser Gly Ser Pro Pro Ala Thr Thr Pro Gln Cys Trp Glu Ser Gln Gly                 325 330 335 Cys Pro Ser Thr Pro Asn Asp Asn Asn Leu Leu Ala Ala Gln Arg His             340 345 350 Asn Glu Ala Leu Asn Gly Leu Arg Gln Gly Pro Ser Ser Tyr Pro Pro         355 360 365 Thr Trp Pro Ser Gly Pro Ala His His Ser Cys His Gln Pro Asn Ser     370 375 380 Asn Gly His Arg Leu Cys Pro Thr His Val Tyr Ser Ala Pro Glu Gly 385 390 395 400 Lys Ala Pro Ala Asn Gly Leu Arg Gln Gly Asn Thr Lys Asn Val Leu                 405 410 415 Leu Ala Cys Pro Met Met Met Tyr Pro His Gly Arg Ser Gly Arg Thr             420 425 430 Val Gln Glu Ile Trp Glu Asp Phe Ser Met Ser Phe Thr Pro Ala Val         435 440 445 Arg Glu Val Val Glu Phe Ala Lys His Ile Pro Gly Phe Arg Asp Leu     450 455 460 Ser Gln His Asp Gln Val Thr Leu Leu Lys Ala Gly Thr Phe Glu Val 465 470 475 480 Leu Met Val Arg Phe Ala Ser Leu Phe Asn Val Lys Asp Gln Thr Val                 485 490 495 Met Phe Leu Ser Arg Thr Thr Tyr Ser Leu Gln Glu Leu Gly Ala Met             500 505 510 Gly Met Gly Asp Leu Leu Asn Ala Met Phe Asp Phe Ser Glu Lys Leu         515 520 525 Asn Ser Leu Ala Leu Thr Glu Glu Glu Leu Gly Leu Phe Thr Ala Val     530 535 540 Val Leu Val Ser Ala Asp Arg Ser Gly Met Glu Asn Ser Ala Ser Val 545 550 555 560 Glu Gln Leu Gln Glu Thr Leu Leu Arg Ala Leu Arg Ala Leu Val Leu                 565 570 575 Lys Asn Arg Pro Ser Glu Thr Ser Arg Phe Thr Lys Leu Leu Leu Lys             580 585 590 Leu Pro Asp Leu Arg Thr Leu Asn Asn Met His Ser Glu Lys Leu Leu         595 600 605 Ser Phe Arg Val Asp Ala Gln     610 615 <210> 4 <211> 497 <212> PRT <213> human <400> 4 Met Pro Thr Pro Asp Ala Thr Thr Pro Gln Ala Lys Gly Phe Arg Arg   1 5 10 15 Ala Val Ser Glu Leu Asp Ala Lys Gln Ala Glu Ala Ile Met Ser Pro              20 25 30 Arg Phe Ile Gly Arg Arg Gln Ser Leu Ile Glu Asp Ala Arg Lys Glu          35 40 45 Arg Glu Ala Ala Val Ala Ala Ala Ala Val Val Ser Glu Pro      50 55 60 Gly Asp Pro Leu Glu Ala Val Ala Phe Glu Glu Lys Glu Gly Lys Ala  65 70 75 80 Val Leu Asn Leu Leu Phe Ser Pro Arg Ala Thr Lys Pro Ser Ala Leu                  85 90 95 Ser Arg Ala Val Lys Val Phe Glu Thr Phe Glu Ala Lys Ile His His             100 105 110 Leu Glu Thr Arg Pro Ala Gln Arg Pro Ala Gly Gly Pro His Leu         115 120 125 Glu Tyr Phe Val Arg Leu Glu Val Arg Arg Gly Asp Leu Ala Ala Leu     130 135 140 Leu Ser Gly Val Arg Glu Val Ser Glu Asp Val Arg Ser Ser Ala Gly 145 150 155 160 Pro Lys Val Pro Trp Phe Pro Arg Lys Val Ser Glu Leu Asp Lys Cys                 165 170 175 His His Leu Val Thr Lys Phe Asp Pro Asp Leu Asp Leu Asp His Pro             180 185 190 Gly Phe Ser Asp Gln Val Tyr Arg Gln Arg Arg Lys Leu Ile Ala Glu         195 200 205 Ile Ala Phe Gln Tyr Arg His Gly Asp Pro Ile Pro Arg Val Glu Tyr     210 215 220 Thr Ala Glu Glu Ile Ala Thr Trp Lys Glu Val Tyr Thr Thr Leu Lys 225 230 235 240 Gly Leu Tyr Ala Thr His Ala Cys Gly Glu His Leu Glu Ala Phe Ala                 245 250 255 Leu Leu Glu Arg Phe Ser Gly Tyr Arg Glu Asp Asn Ile Pro Gln Leu             260 265 270 Glu Asp Val Ser Arg Phe Leu Lys Glu Arg Thr Gly Phe Gln Leu Arg         275 280 285 Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe Leu Ala Ser Leu Ala     290 295 300 Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg His Ala Ser Ser Pro 305 310 315 320 Met His Ser Pro Glu Pro Asp Cys Cys His Glu Leu Leu Gly His Val                 325 330 335 Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe Ser Gln Asp Ile Gly             340 345 350 Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile Glu Lys Leu Ser Thr         355 360 365 Leu Tyr Trp Phe Thr Val Glu Phe Gly Leu Cys Lys Gln Asn Gly Glu     370 375 380 Val Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser Tyr Gly Glu Leu Leu 385 390 395 400 His Cys Leu Ser Glu Glu Pro Glu Ile Arg Ala Phe Asp Pro Glu Ala                 405 410 415 Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr Gln Ser Val Tyr Phe             420 425 430 Val Ser Glu Ser Phe Ser Asp Ala Lys Asp Lys Leu Arg Ser Tyr Ala         435 440 445 Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe Asp Pro Tyr Thr Leu     450 455 460 Ala Ile Asp Val Leu Asp Ser Pro Gln Ala Val Arg Arg Ser Leu Glu 465 470 475 480 Gly Val Gln Asp Glu Leu Asp Thr Leu Ala His Ala Leu Ser Ala Ile                 485 490 495 Gly     <210> 5 <211> 498 <212> PRT <213> mouse <400> 5 Met Pro Thr Pro Ser Ser Ser Ser Pro Gln Pro Lys Gly Phe Arg Arg   1 5 10 15 Ala Val Ser Glu Gln Asp Thr Lys Gln Ala Glu Ala Val Thr Ser Pro              20 25 30 Arg Phe Ile Gly Arg Arg Gln Ser Leu Ile Glu Asp Ala Arg Lys Glu          35 40 45 Arg Glu Ala Ala Ala Ala Ala Ala Ala Val Ala Ser Ala Glu      50 55 60 Pro Gly Asn Pro Leu Glu Ala Val Val Phe Glu Glu Arg Asp Gly Asn  65 70 75 80 Ala Val Leu Asn Leu Leu Phe Ser Leu Arg Gly Thr Lys Pro Ser Ser                  85 90 95 Leu Ser Arg Ala Leu Lys Val Phe Glu Thr Phe Glu Ala Lys Ile His             100 105 110 His Leu Glu Thr Arg Pro Ala Gln Arg Pro Leu Ala Gly Ser Pro His         115 120 125 Leu Glu Tyr Phe Val Arg Phe Glu Val Ser Gly Asp Leu Ala Ala     130 135 140 Leu Leu Ser Ser Val Arg Arg Val Ser Asp Val Val Arg Ser Ala Arg 145 150 155 160 Glu Asp Lys Val Pro Trp Phe Pro Arg Lys Val Ser Glu Leu Asp Lys                 165 170 175 Cys His His Leu Val Thr Lys Phe Asp Pro Asp Leu Asp Leu Asp His             180 185 190 Pro Gly Phe Ser Asp Gln Ala Tyr Arg Gln Arg Arg Lys Leu Ile Ala         195 200 205 Glu Ile Ala Phe Gln Tyr Lys Gln Gly Glu Pro Ile Pro His Val Glu     210 215 220 Tyr Thr Lys Glu Glu Ile Ala Thr Trp Lys Glu Val Tyr Ala Thr Leu 225 230 235 240 Lys Gly Leu Tyr Ala Thr His Ala Cys Arg Glu His Leu Glu Ala Phe                 245 250 255 Gln Leu Leu Glu Arg Tyr Cys Gly Tyr Arg Glu Asp Ser Ile Pro Gln             260 265 270 Leu Glu Asp Val Ser His Phe Leu Lys Glu Arg Thr Gly Phe Gln Leu         275 280 285 Arg Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe Leu Ala Ser Leu     290 295 300 Ala Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg His Ala Ser Ser 305 310 315 320 Pro Met His Ser Pro Glu Pro Asp Cys Cys His Glu Leu Leu Gly His                 325 330 335 Val Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe Ser Gln Asp Ile             340 345 350 Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile Glu Lys Leu Ser         355 360 365 Thr Val Tyr Trp Phe Thr Val Glu Phe Gly Leu Cys Lys Gln Asn Gly     370 375 380 Glu Leu Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser Tyr Gly Glu Leu 385 390 395 400 Leu His Ser Leu Ser Glu Glu Pro Glu Val Arg Ala Phe Asp Pro Asp                 405 410 415 Thr Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr Gln Pro Val Tyr             420 425 430 Phe Val Ser Glu Ser Phe Ser Asp Ala Lys Asp Lys Leu Arg Asn Tyr         435 440 445 Ala Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe Asp Pro Tyr Thr     450 455 460 Leu Ala Ile Asp Val Leu Asp Ser Pro His Thr Ile Arg Arg Ser Leu 465 470 475 480 Glu Gly Val Gln Asp Glu Leu His Thr Leu Thr Gln Ala Leu Ser Ala                 485 490 495 Ile Ser         <210> 6 <211> 498 <212> PRT <213> rat <400> 6 Met Pro Thr Pro Ser Ala Pro Ser Pro Gln Pro Lys Gly Phe Arg Arg   1 5 10 15 Ala Val Ser Glu Gln Asp Ala Lys Gln Ala Glu Ala Val Thr Ser Pro              20 25 30 Arg Phe Ile Gly Arg Arg Gln Ser Leu Ile Glu Asp Ala Arg Lys Glu          35 40 45 Arg Glu Ala Ala Ala Ala Ala Ala Ala Val Ala Ser Ser Glu      50 55 60 Pro Gly Asn Pro Leu Glu Ala Val Val Phe Glu Glu Arg Asp Gly Asn  65 70 75 80 Ala Val Leu Asn Leu Leu Phe Ser Leu Arg Gly Thr Lys Pro Ser Ser                  85 90 95 Leu Ser Arg Ala Val Lys Val Phe Glu Thr Phe Glu Ala Lys Ile His             100 105 110 His Leu Glu Thr Arg Pro Ala Gln Arg Pro Leu Ala Gly Ser Pro His         115 120 125 Leu Glu Tyr Phe Val Arg Phe Glu Val Ser Gly Asp Leu Ala Ala     130 135 140 Leu Leu Ser Ser Val Arg Arg Val Ser Asp Val Val Arg Ser Ala Arg 145 150 155 160 Glu Asp Lys Val Pro Trp Phe Pro Arg Lys Val Ser Glu Leu Asp Lys                 165 170 175 Cys His His Leu Val Thr Lys Phe Asp Pro Asp Leu Asp Leu Asp His             180 185 190 Pro Gly Phe Ser Asp Gln Val Tyr Arg Gln Arg Arg Lys Leu Ile Ala         195 200 205 Glu Ile Ala Phe Gln Tyr Lys His Gly Glu Pro Ile Pro His Val Glu     210 215 220 Tyr Thr Ala Glu Glu Ile Ala Thr Trp Lys Glu Val Tyr Val Thr Leu 225 230 235 240 Lys Gly Leu Tyr Ala Thr His Ala Cys Arg Glu His Leu Glu Gly Phe                 245 250 255 Gln Leu Leu Glu Arg Tyr Cys Gly Tyr Arg Glu Asp Ser Ile Pro Gln             260 265 270 Leu Glu Asp Val Ser Arg Phe Leu Lys Glu Arg Thr Gly Phe Gln Leu         275 280 285 Arg Pro Val Ala Gly Leu Leu Ser Ala Arg Asp Phe Leu Ala Ser Leu     290 295 300 Ala Phe Arg Val Phe Gln Cys Thr Gln Tyr Ile Arg His Ala Ser Ser 305 310 315 320 Pro Met His Ser Pro Glu Pro Asp Cys Cys His Glu Leu Leu Gly His                 325 330 335 Val Pro Met Leu Ala Asp Arg Thr Phe Ala Gln Phe Ser Gln Asp Ile             340 345 350 Gly Leu Ala Ser Leu Gly Ala Ser Asp Glu Glu Ile Glu Lys Leu Ser         355 360 365 Thr Val Tyr Trp Phe Thr Val Glu Phe Gly Leu Cys Lys Gln Asn Gly     370 375 380 Glu Leu Lys Ala Tyr Gly Ala Gly Leu Leu Ser Ser Tyr Gly Glu Leu 385 390 395 400 Leu His Ser Leu Ser Glu Glu Pro Glu Val Arg Ala Phe Asp Pro Asp                 405 410 415 Thr Ala Ala Val Gln Pro Tyr Gln Asp Gln Thr Tyr Gln Pro Val Tyr             420 425 430 Phe Val Ser Glu Ser Phe Asn Asp Ala Lys Asp Lys Leu Arg Asn Tyr         435 440 445 Ala Ser Arg Ile Gln Arg Pro Phe Ser Val Lys Phe Asp Pro Tyr Thr     450 455 460 Leu Ala Ile Asp Val Leu Asp Ser Pro His Thr Ile Gln Arg Ser Leu 465 470 475 480 Glu Gly Val Gln Asp Glu Leu His Thr Leu Ala His Ala Leu Ser Ala                 485 490 495 Ile Ser         <210> 7 <211> 2793 <212> DNA <213> human <400> 7 gggcacgagg cgctccctgg gatcacatgg tacctgctcc agtgccgcgt gcggcccggg 60 aaccctgggc tgctggcgcc tgcgcagagc cctctgtccc agggaaaggc tcgggcaaaa 120 ggcggctgag attggcagag tgaaatatta ctgccgaggg aacgtagcag ggcacacgtc 180 tcgcctcttt gcgactcggt gccccgtttc tccccatcac ctacttactt cctggttgca 240 acctctcttc ctctgggact tttgcaccgg gagctccaga ttcgccaccc cgcagcgctg 300 cggagccggc aggcagaggc accccgtaca ctgcagagac ccgaccctcc ttgctacctt 360 ctagccagaa ctactgcagg ctgattcccc ctacacactc tctctgctct tcccatgcaa 420 agcagaactc cgttgcctca acgtccaacc cttctgcagg gctgcagtcc ggccacccca 480 agaccttgct gcagggtgct tcggatcctg atcgtgagtc gcggggtcca ctccccgccc 540 ttagccagtg cccagggggc aacagcggcg atcgcaacct ctagtttgag tcaaggtcca 600 gtttgaatga ccgctctcag ctggtgaaga catgacgacc ctggactcca acaacaacac 660 aggtggcgtc atcacctaca ttggctccag tggctcctcc ccaagccgca ccagccctga 720 atccctctat agtgacaact ccaatggcag cttccagtcc ctgacccaag gctgtcccac 780 ctacttccca ccatccccca ctggctccct cacccaagac ccggctcgct cctttgggag 840 cattccaccc agcctgagtg atgacggctc cccttcttcc tcatcttcct cgtcgtcatc 900 ctcctcctcc ttctataatg ggagcccccc tgggagtcta caagtggcca tggaggacag 960 cagccgagtg tcccccagca agagcaccag caacatcacc aagctgaatg gcatggtgtt 1020 actgtgtaaa gtgtgtgggg acgttgcctc gggcttccac tacggtgtgc acgcctgcga 1080 gggctgcaag ggctttttcc gtcggagcat ccagcagaac atccagtaca aaaggtgtct 1140 gaagaatgag aattgctcca tcgtccgcat caatcgcaac cgctgccagc aatgtcgctt 1200 caagaagtgt ctctctgtgg gcatgtctcg agacgctgtg cgttttgggc gcatccccaa 1260 acgagagaag cagcggatgc ttgctgagat gcagagtgcc atgaacctgg ccaacaacca 1320 gttgagcagc cagtgcccgc tggagacttc acccacccag caccccaccc caggccccat 1380 gggcccctcg ccaccccctg ctccggtccc ctcacccctg gtgggcttct cccagtttcc 1440 acaacagctg acgcctccca gatccccaag ccctgagccc acagtggagg atgtgatatc 1500 ccaggtggcc cgggcccatc gagagatctt cacctacgcc catgacaagc tgggcagctc 1560 acctggcaac ttcaatgcca accatgcatc aggtagccct ccagccacca ccccacatcg 1620 ctgggaaaat cagggctgcc cacctgcccc caatgacaac aacaccttgg ctgcccagcg 1680 tcataacgag gccctaaatg gtctgcgcca ggctccctcc tcctaccctc ccacctggcc 1740 tcctggccct gcacaccaca gctgccacca gtccaacagc aacgggcacc gtctatgccc 1800 cacccacgtg tatgcagccc cagaaggcaa ggcacctgcc aacagtcccc ggcagggcaa 1860 ctcaaagaat gttctgctgg catgtcctat gaacatgtac ccgcatggac gcagtgggcg 1920 aacggtgcag gagatctggg aggatttctc catgagcttc acgcccgctg tgcgggaggt 1980 ggtagagttt gccaaacaca tcccgggctt ccgtgacctt tctcagcatg accaagtcac 2040 cctgcttaag gctggcacct ttgaggtgct gatggtgcgc tttgcttcgt tgttcaacgt 2100 gaaggaccag acagtgatgt tcctaagccg caccacctac agcctgcagg agcttggtgc 2160 catgggcatg ggagacctgc tcagtgccat gttcgacttc agcgagaagc tcaactccct 2220 ggcgcttacc gaggaggagc tgggcctctt caccgcggtg gtgcttgtct ctgcagaccg 2280 ctcgggcatg gagaattccg cttcggtgga gcagctccag gagacgctgc tgcgggctct 2340 tcgggctctg gtgctgaaga accggccctt ggagacttcc cgcttcacca agctgctgct 2400 caagctgccg gacctgcgga ccctgaacaa catgcattcc gagaagctgc tgtccttccg 2460 ggtggacgcc cagtgacccg cccggccggc cttctgccgc tgcccccttg tacagaatcg 2520 aactctgcac ttctctctcc tttacgagac gaaaaggaaa agcaaaccag aatcttattt 2580 atattgttat aaaatattcc aagatgagcc tctggccccc tgagccttct tgtaaatacc 2640 tgcctccctc ccccatcacc gaacttcccc tcctccccta tttaaaccac tctgtctccc 2700 ccacaaccct cccctggccc tctgatttgt tctgttcctg tctcaaatcc aatagttcac 2760 agctgagctg gcttcaaaaa aaaaaaaaaa aaa 2793 <210> 8 <211> 2782 <212> DNA <213> mouse <400> 8 actggggcac gaggcgctcc ctggaatcac atggtacctg ctccagtgcc gcgtgcggcc 60 cgggaaccct gggctgctgg cgcctgcgca gagccctctg tcccagggaa aggctcgggc 120 aaaaggcggt tgagattggc agagtgaaat attactgctg aggaaacgta gcagggcaca 180 cgtctctctt tgcgtcctgg tgcctcattt ctccatcacc tacttacttc ctggttgcag 240 cttctcttcc tttgggactt ttgcacccgg agctccagat tcattaccct gcttcactgc 300 ggagccttca ggagtggcat ccggtgcact gcagagaccc gactctcctt gctaccttat 360 agccagaact gctgcaggct gattcttcac acacacactc tctgctcttc ccatgcaaat 420 cagatctcag gtgcctcagc gtcctaccct tctggagggc tgcagtatag ccaccccaag 480 accttactgc tcagtgcctg gaatcctgat tgcgaactgc ggggctcact cgtctccctc 540 agccattgcc cagggggcga gagaggccat cacaacctcc agtttgtgtc aaggtccagt 600 ttgaatgacc gctttcagct ggtgaagaca tgacgaccct ggactccaat aacaacacag 660 gtggtgttat cacctacatt ggctctagtg gctcctcccc gagccggacc agcccggagt 720 ccctctacag tgacagctcc aatggcagct tccagtccct gactcaaggt tgtcccacat 780 acttcccacc atcacctact ggctccctca cccaggaccc tgcccgctct tttggcagtg 840 cgccacccag tctcagtgat gatagctccc cttcttctgc atcatcgtca tcctcttcat 900 cctcctcctc cttctataac gggagccccc caggaagtct acaagtggcc atggaagaca 960 gcagccgagt gtcccccagc aagggcacaa gcaacattac caagctgaat ggcatggtgc 1020 tactgtgtaa ggtgtgtggg gacgtggcct caggcttcca ctatggagtg cacgcctgtg 1080 agggctgcaa gggctttttt cgccggagca tccaacagaa tatccagtac aaacggtgtc 1140 tgaaaaacga aaactgctcc atcgttcgca tcaatcgcaa ccgctgccag cagtgtcgct 1200 tcaagaagtg tctctccgtt ggcatgtcta gagatgctgt gcgttttggg cgcatcccca 1260 agagagagaa gcaacggatg cttgccgaga tgcagagcgc catgaacttg gccaacaacc 1320 aactgagcag cctgtgccct ctagagacct cacctactcc acatcccacc tctggctcca 1380 tgggcccctc acctcctcct gcaccagccc ccacaccttt ggtgggcttc tctcagttcc 1440 cacaacagct gacaccaccc aggtctccca gccctgagcc caccatggag gatgtgatat 1500 cccaggtcgc ccgggcccat cgagaaatct tcacctatgc ccatgacaag ttaggcacct 1560 cacctggtaa cttcaatgcc aatcatgcat caggtagccc ttcagctaca actccacacc 1620 gctgggagag tcagggatgc ccgtctgccc ccaacgacaa caaccttttg gcggctcagc 1680 gtcataatga agcgctgaat ggtctacgcc agggcccttc ctcctacccg cctacctggc 1740 cctctggccc cacccaccac agctgccacc aacctaacag caatgggcac cgtctgtgcc 1800 ccacccacgt atattcggcc ccagaagggg aggcacctgc caacagtcta cggcaaggca 1860 acaccaagaa tgttctgctg gcatgtccca tgaacatgta tccccatgga cgcagcggcc 1920 ggactgtgca ggagatctgg gaagacttct ctatgagctt cacgcctgcc gttcgggagg 1980 tggtagagtt tgccaaacac atcccaggct tccgtgacct ttctcagcac gaccaggtga 2040 ccctgcttaa ggctggcacc tttgaggtgc tgatggtgcg ctttgcatcg ttgttcaacg 2100 tgaaggacca gacagtgatg ttcctgagcc gcacaaccta cagtctgcag gagctcggtg 2160 ccatgggcat gggcgacctg ctcaatgcca tgtttgactt cagcgagaag ctcaactccc 2220 tggcacttac cgaggaggag ctgggcctat tcaccgcggt ggtgcttgtc tctgcagacc 2280 gctcgggaat ggagaattcc gcttcggtgg agcagctcca ggagacgctg ctgcgggctc 2340 ttcgggctct ggtgctgaag aaccggccct cggagacttc ccgcttcacc aagctgctgc 2400 tcaagctgcc ggacctgcgg accctgaaca acatgcattc cgagaagctg ctgtccttcc 2460 gggtggacgc ccagtgaccc gcccggccgg ccttctgccg ctgccccctt gtacagaatc 2520 gaactctgca cttctctctc ctttacgaga cgaaaaggaa aagcaaacca gaatcttatt 2580 tatattgtta taaaatattc caagatgagc ctctggcccc ctgagccttc ttgtaaataa 2640 ctcttccccc acccccaccg ccatgctccc atcctcccct atttaaacca ctcttgctct 2700 ctccaccctc ctctggcccc tcgatttgtt ctgttcctgt ctcaaatcca atagttcaca 2760 gctgaaaaaa aaaaaaaaaa aa 2782 <210> 9 <211> 2344 <212> DNA <213> rat <400> 9 tcagatctcg gttgcctcag catcctaccc ttctggaggg ctgcagtata gccaccccaa 60 gaccttactg ctcggtgcct agaatcctga ttgtgaactg cgggcttcac tcgtctctct 120 cagccattgc ccacggggcg agagagggca ccacaacctc cactttgtgt caaggtccag 180 tttgaatgac cgctttcagc tggtgaagac atgacgaccc tagactccaa caacaacaca 240 ggtggtgtta tcacctacat tggctccagc ggatcctccc ccagccggac cagcccagag 300 tccctctata gtgacagctc caatggcagc ttccagtccc tgactcaagg ttgtcccaca 360 tacttcccac catcacctac tggctccctc acccaggacc ctgcccgctc atttggcact 420 gtgccaccca gcctcagtga tgatagctcc ccttcttctg cttcatcatc atcatcatct 480 tcctcctcct ccttctataa tgggagcccc cccggaagtc tacaagtggc catggaagac 540 agcagccgag tgtcccccag caagggcacc agcaacatta ccaagcttaa cggcatggtg 600 ctactgtgta aagtgtgtgg ggacgtggcc tcaggcttcc actatggcgt gcatgcctgc 660 gagggctgca agggcttttt ccgccggagc atccagcaga acatccagta caagcggtgt 720 ttgaaaaacg agaactgctc cattgtccgt atcaatcgca accgctgcca gcagtgtcgc 780 ttcaagaagt gtctctccgt tggcatgtct agagacgctg tgcgttttgg acgtatcccc 840 aagagagaga agcaacgaat gcttgctgag atgcagaacg ccatgaactt ggccaacaac 900 caactgagca gcctgtgccc tctagagacc tcacctgccc cgcaccccac ctcaggctcc 960 gtgggcccct caccacctcc tgcaccagcc ccgacacctt tggtgggctt ctctcagttc 1020 ccacaacagc tgacaccacc cagatccccg agtcctgagc ccaccgtgga ggatgtgata 1080 tcccaggtgg ccagggccca tcgagaaatc ttcacctatg cccatgacaa attaggcacc 1140 tcacctggca acttcaatgc caatcatgca tcaggtagcc ctccggctac cactccacag 1200 tgctgggaga gtcagggatg cccgtctacc cccaacgaca acaacctttt ggcggctcag 1260 cgtcataatg aagcactgaa tggtctacgc cagggcccct cctcctaccc tcctacctgg 1320 ccttctggcc ctgcccacca cagctgccac cagcctaaca gcaatgggca tcgcctgtgc 1380 cccacccacg tatactcggc cccagaaggc aaggcacctg ccaacggtct acggcaaggc 1440 aacaccaaga atgttctgct ggcatgtccc atgaacatgt atccccatgg acgtagtggc 1500 cggactgtgc aggagatctg ggaagacttc tctatgagct tcacacccgc tgtgcgggag 1560 gtggtagaat ttgccaaaca catccccggc ttccgtgacc tttctcagca cgaccaggtg 1620 accctgctta aggctggcac ctttgaggtg ctgatggtgc gctttgcgtc attgttcaac 1680 gtgaaggacc agacagtcat gttcctgagc cgcacaacct acagcctgca ggagctcggt 1740 gccatgggca tgggtgacct gctcaatgcc atgtttgact tcagcgagaa gctcaactct 1800 ctggcgctta ctgaggagga gctgggcctt ttcacggcag tggtacttgt ctctgcagac 1860 cgctcgggaa tggagaattc cgcttcggtg gagcagctcc aggagacgct gctgcgggct 1920 cttcgggctc tggtgctgaa gaaccggccc tcggagactt cccgcttcac caaactgctg 1980 ctcaagctgc cggacctgcg gaccctgaac aacatgcatt ccgagaagct gctgtccttc 2040 cgggtggacg cccagtgacc cgcccggccg gccttctgcc gctgccccct tgtacagaat 2100 cgaactctgc acttctctct cctttacgag acgaaaagga aaagcaaacc agaatcttat 2160 ttatattgtt ataaaatatt ccaagatgag cctctggccc cctgagcctt cttgtaaata 2220 actcttcccc cccaccccca tgctcccttc ctcccgtatt taaaccactc ttgctctccc 2280 accctcctct ggcccctcga tttgttctgt tcctgtctca aatccaatag ttcacagctg 2340 aaaa 2344 <210> 10 <211> 1817 <212> DNA <213> human <400> 10 cggacctcca cactgagcca tgcccacccc cgacgccacc acgccacagg ccaagggctt 60 ccgcagggcc gtgtctgagc tggacgccaa gcaggcagag gccatcatgt ccccgcggtt 120 cattgggcgc aggcagagcc tcatcgagga cgcccgcaag gagcgggagg cggcggtggc 180 agcagcggcc gctgcagtcc cctcggagcc cggggacccc ctggaggctg tggcctttga 240 gggaaggag gggaaggccg tgctaaacct gctcttctcc ccgagggcca ccaagccctc 300 ggcgctgtcc cgagctgtga aggtgtttga gacgtttgaa gccaaaatcc accatctaga 360 gacccggccc gcccagaggc cgcgagctgg gggcccccac ctggagtact tcgtgcgcct 420 cgaggtgcgc cgaggggacc tggccgccct gctcagtggt gtgcgccagg tgtcagagga 480 cgtgcgcagc cccgcggggc ccaaggtccc ctggttccca agaaaagtgt cagagctgga 540 caagtgtcat cacctggtca ccaagttcga ccctgacctg gacttggacc acccgggctt 600 ctcggaccag gtgtaccgcc agcgcaggaa gctgattgct gagatcgcct tccagtacag 660 gcacggcgac ccgattcccc gtgtggagta caccgccgag gagattgcca cctggaagga 720 ggtctacacc acgctgaagg gcctctacgc cacgcacgcc tgcggggagc acctggaggc 780 ctttgctttg ctggagcgct tcagcggcta ccgggaagac aatatccccc agctggagga 840 cgtctcccgc ttcctgaagg agcgcacggg cttccagctg cggcctgtgg ccggcctgct 900 gtccgcccgg gacttcctgg ccagcctggc cttccgcgtg ttccagtgca cccagtatat 960 ccgccacgcg tcctcgccca tgcactcccc tgagccggac tgctgccacg agctgctggg 1020 gcacgtgccc atgctggccg accgcacctt cgcgcagttc tcgcaggaca ttggcctggc 1080 gtccctgggg gcctcggatg aggaaattga gaagctgtcc acgctgtact ggttcacggt 1140 ggagttcggg ctgtgtaagc agaacgggga ggtgaaggcc tatggtgccg ggctgctgtc 1200 ctcctacggg gagctcctgc actgcctgtc tgaggagcct gagattcggg ccttcgaccc 1260 tgaggctgcg gccgtgcagc cctaccaaga ccagacgtac cagtcagtct acttcgtgtc 1320 tgagagcttc agtgacgcca aggacaagct caggagctat gcctcacgca tccagcgccc 1380 cttctccgtg aagttcgacc cgtacacgct ggccatcgac gtgctggaca gcccccaggc 1440 cgtgcggcgc tccctggagg gtgtccagga tgagctggac acccttgccc atgcgctgag 1500 tgccattggc taggtgcacg gcgtccctga gggcccttcc caacctcccc tggtcctgca 1560 ctgtcccgga gctcaggccc tggtgagggg ctgggtcccg ggtgcccccc atgccctccc 1620 tgctgccagg ctcccactgc ccctgcacct gcttctcagc gcaacagctg tgtgtgcccg 1680 tggtgaggtt gtgctgcctg tggtgaggtc ctgtcctggc tcccagggtc ctgggggctg 1740 ctgcactgcc ctccgccctt ccctgacact gtctgctgcc ccaatcaccg tcacaataaa 1800 agaaactgtg gtctcta 1817 <210> 11 <211> 1757 <212> DNA <213> mouse <400> 11 gcactatgcc cacccccagc gcctcctcgc cacagcccaa gggcttcaga agagccgtct 60 cagagcagga taccaagcag gccgaggctg tcacgtcccc aaggttcatt ggacggcggc 120 agagtctcat cgaggatgcc cgcaaggagc gggaggcagc agcagctgca gcagcggctg 180 cggtagcctc cgcggaacct gggaacccat tggaggctgt ggtattcgag gagagggatg 240 gaaatgctgt tctcaacctg ctcttctcct tgaggggtac aaaaccctcc tcactgtctc 300 gggctttgaa agtgtttgag acatttgaag ccaaaatcca ccacttagag acccggcctg 360 cccagaggcc actggcagga agcccccacc tggagtactt tgtgcgcttc gaggtgccca 420 gtggcgacct ggctgccctc ctcagttctg tgcgtcgggt gtctgacgat gtgcgcagtg 480 ccagagagga caaggttccc tggttcccaa ggaaagtgtc agagttggat aagtgtcacc 540 acctggtcac caagtttgac cctgacctgg acctggacca tccgggcttc tctgaccagg 600 cgtatcgcca gcgccggaag ctgattgcag agattgcctt ccaatacaag cagggtgagc 660 caattcccca cgtggaatac acaaaggagg aaattgctac ctggaaggag gtatacgcca 720 cgctgaaggg cctctatgct acccatgcct gccgggaaca cctggaggct ttccagcttc 780 tggaacggta ctgtggctac cgagaggaca gcattccaca gctggaggat gtgtctcact 840 tcttgaagga acggactggc ttccagctgc gacccgtggc cggtctactg tctgcccgtg 900 attttctggc cagtctggcc ttccgtgtgt ttcagtgcac acagtacatc cgtcatgcct 960 cctcacctat gcactcaccc gagccagact gctgccacga gctgctggga cacgtaccca 1020 tgttggctga ccgcacattt gcccagttct cccaggacat tggacttgca tctctggggg 1080 cttcagatga agaaattgaa aaactctcca cggtgtactg gttcactgtg gagtttgggc 1140 tgtgtaaaca gaatggggag ctgaaggctt acggtgcagg gctgctgtct tcctatggag 1200 agctcctgca ctccctgtca gaggagcccg aggtccgggc ctttgaccca gacacagcag 1260 ccgtgcagcc ctaccaagat caaacctacc agccggtgta cttcgtgtca gagagcttca 1320 gtgatgccaa ggacaagctc aggaactatg cctctcgtat ccagcgccca ttctctgtga 1380 agtttgaccc gtacaccctg gccattgatg tactggacag tcctcacacc atccggcgct 1440 ccttagaggg ggtccaggat gagctgcaca ccctgaccca agcactgagt gccattagct 1500 aaatgcatag ggtaccaccc acaggtgcca ggggcctttc ccaaagttcc cagccccttc 1560 tccaaccttt cctggcccag aggctttccc atgtgtgtgg ctggaccctt tgatgggctg 1620 ctcttggtcc ccctcctcca ctgcttctca accacatctt actactgcat gcgctccagg 1680 atggtcctgc attcctcctg cccttcatgc tgtattctac cctgattatt atctcaataa 1740 aggaaggaaa ggtctcc 1757 <210> 12 <211> 1770 <212> DNA <213> rat <400> 12 cagcttgcac tatgcccacc cccagcgccc cctcgccaca gcccaagggc ttcagaaggg 60 ccgtctcaga gcaggatgcc aagcaggccg aggctgtcac gtccccaagg ttcatcggac 120 ggcgacagag tctcatcgag gatgcccgca aggagcggga ggcggcggca gctgcagcag 180 cagcagcggt agcctcctcg gaacctggga acccactgga ggctgtggta tttgaggaga 240 gggatgggaa tgctgttctc aacctgctct tctccctgag gggtacaaaa ccctcctcct 300 tgtctcgggc tgtaaaagta tttgagacat ttgaagccaa aattcaccac ttagagaccc 360 ggcctgccca gaggccactg gcaggaagcc cccacctgga gtattttgtg cgcttcgagg 420 tgcccagtgg agacctggct gccctcctca gctctgtgcg tcgggtgtct gacgacgtgc 480 gcagtgccag agaggacaag gtcccctggt tcccaagaaa agtgtcggaa ttggacaagt 540 gtcaccacct ggtcaccaag tttgaccctg atctggacct ggaccacccg ggcttctctg 600 accaggtgta tcgccagcgt cggaagctga ttgcagagat tgccttccag tacaagcacg 660 gtgaaccaat tccccatgtg gaatacacag cggaagagat tgctacctgg aaggaggtat 720 atgtcacgct gaagggcctc tatgctaccc atgcctgccg ggagcacctg gagggtttcc 780 agcttctgga acggtactgt ggctaccgag aggacagcat cccacagctg gaggacgtgt 840 cccgcttctt gaaggagcgg actggcttcc agctgcgacc cgtggccggt ctactgtccg 900 cccgtgattt tctggccagt ctggccttcc gcgtgtttca atgcacccag tatatccgcc 960 atgcctcctc acctatgcat tcacctgagc cggactgctg ccatgagctg ttgggacatg 1020 tacccatgtt ggctgaccgc acatttgccc agttctccca ggacattgga cttgcatctc 1080 tgggggcctc agatgaagaa attgaaaaac tctccacggt gtactggttc actgtggaat 1140 tcgggctatg taaacagaat ggggagctga aggcttatgg tgcagggctg ctgtcttcct 1200 acggagagct cctgcactcc ctgtcagagg agcctgaggt ccgagccttt gcccagaca 1260 cagcagctgt gcagccctac caagatcaaa cctaccagcc tgtgtacttt gtgtccgaga 1320 gcttcaatga cgccaaggac aagctcagga actatgcctc tcgtatccag cgcccattct 1380 ctgtgaagtt tgacccgtac acactggcca ttgacgtact ggacagccct cacaccatcc 1440 agcgctcctt ggagggggtc caggatgagc tgcacaccct ggcccacgca ctgagtgcca 1500 ttagctaaat gcatagggta ccacccacag gtgccagggc ctttcccaaa gtctccatcc 1560 ccttctccaa cctttcctgg cccagaggct ttcccatgtg tgtggctggg ccctttgatg 1620 ggctcctctt ggacccccat cctcccaaca ctgcttctca accatgtctt actactgcat 1680 gcactccagg gtggtcctgc attcctcctg ccctccatgc tctatactac cctgattatt 1740 ctctcaataa aggaaggaaa gaatctaacc 1770 <210> 13 <211> 598 <212> PRT <213> human <400> 13 Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser   1 5 10 15 Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser              20 25 30 Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn          35 40 45 Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met      50 55 60 Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln  65 70 75 80 Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln                  85 90 95 Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu             100 105 110 Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro         115 120 125 Thr Pro Thr Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp     130 135 140 Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr 145 150 155 160 His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe                 165 170 175 Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met             180 185 190 Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly         195 200 205 Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile     210 215 220 Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala 225 230 235 240 Ser Gln Leu Leu Asp Thr Gln Val Ser Pro Pro Ser Ser Gly Ser                 245 250 255 Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys             260 265 270 Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys         275 280 285 Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn     290 295 300 Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe 305 310 315 320 Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp                 325 330 335 Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro             340 345 350 Gln Glu Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu         355 360 365 Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr     370 375 380 Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr 385 390 395 400 Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile                 405 410 415 Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys             420 425 430 Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val         435 440 445 Leu Arg Leu Ala Tyr Arg Ser Asn Pro Val Glu Gly Lys Leu Ile Phe     450 455 460 Cys Asn Gly Val Val Leu His Arg Leu Gln Cys Val Arg Gly Phe Gly 465 470 475 480 Glu Trp Ile Asp Ser Ile Val Glu Phe Ser Ser Asn Leu Gln Asn Met                 485 490 495 Asn Ile Asp Ile Ser Ala Phe Ser Cys Ile             500 505 510 Thr Glu Arg His Gly Leu Lys Glu Pro Lys Arg Val Glu Glu Leu Gln         515 520 525 Asn Lys Ile Val Asn Cys Leu Lys Asp His Val Thr Phe Asn Asn Gly     530 535 540 Gly Leu Asn Arg Pro Asn Tyr Leu Ser Lys Leu Leu Gly Lys Leu Pro 545 550 555 560 Glu Leu Arg Thr Leu Cys Thr Gln Gly Leu Gln Arg Ile Phe Tyr Leu                 565 570 575 Lys Leu Glu Asp Leu Val Pro Pro Ala Ile Asp Lys Leu Phe             580 585 590 Leu Asp Thr Leu Pro Phe         595 <210> 14 <211> 598 <212> PRT <213> mouse <400> 14 Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser   1 5 10 15 Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser              20 25 30 Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn          35 40 45 Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met      50 55 60 Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln  65 70 75 80 Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln                  85 90 95 Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu             100 105 110 Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro         115 120 125 Thr Pro Ser Thr Pro Ser Phe Gln Val Gln His Ser Pro Met Trp Asp     130 135 140 Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr 145 150 155 160 His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe                 165 170 175 Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met             180 185 190 Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly         195 200 205 Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile     210 215 220 Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala 225 230 235 240 Ser Gln Leu Leu Asp Thr Gln Val Ser Pro Pro Ser Ser Gly Ser                 245 250 255 Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys             260 265 270 Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys         275 280 285 Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn     290 295 300 Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe 305 310 315 320 Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp                 325 330 335 Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro             340 345 350 Gln Asp Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu         355 360 365 Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr     370 375 380 Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr 385 390 395 400 Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile                 405 410 415 Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys             420 425 430 Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val         435 440 445 Leu Arg Leu Ala Tyr Arg Ser Asn Pro Val Glu Gly Lys Leu Ile Phe     450 455 460 Cys Asn Gly Val Val Leu His Arg Leu Gln Cys Val Arg Gly Phe Gly 465 470 475 480 Glu Trp Ile Asp Ser Ile Val Glu Phe Ser Ser Asn Leu Gln Asn Met                 485 490 495 Asn Ile Asp Ile Ser Ala Phe Ser Cys Ile             500 505 510 Thr Glu Arg His Gly Leu Lys Glu Pro Lys Arg Val Glu Glu Leu Gln         515 520 525 Asn Lys Ile Val Asn Cys Leu Lys Asp His Val Thr Phe Asn Asn Gly     530 535 540 Gly Leu Asn Arg Pro Asn Tyr Leu Ser Lys Leu Leu Gly Lys Leu Pro 545 550 555 560 Glu Leu Arg Thr Leu Cys Thr Gln Gly Leu Gln Arg Ile Phe Tyr Leu                 565 570 575 Lys Leu Glu Asp Leu Val Pro Pro Ala Ile Asp Lys Leu Phe             580 585 590 Leu Asp Thr Leu Pro Phe         595 <210> 15 <211> 598 <212> PRT <213> rat <400> 15 Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser   1 5 10 15 Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser              20 25 30 Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn          35 40 45 Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met      50 55 60 Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln  65 70 75 80 Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln                  85 90 95 Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu             100 105 110 Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro         115 120 125 Thr Pro Ser Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp     130 135 140 Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr 145 150 155 160 His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe                 165 170 175 Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met             180 185 190 Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly         195 200 205 Ser His His Val Val Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile     210 215 220 Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala 225 230 235 240 Ser Gln Leu Leu Asp Thr Gln Val Ser Pro Pro Ser Ser Gly Ser                 245 250 255 Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys             260 265 270 Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys         275 280 285 Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu Ala Asn Lys Asn     290 295 300 Cys Pro Val Asp Lys Arg Arg Arg Asn Arg Cys Gln Tyr Cys Arg Phe 305 310 315 320 Gln Lys Cys Leu Ala Val Gly Met Val Lys Glu Val Val Arg Thr Asp                 325 330 335 Ser Leu Lys Gly Arg Arg Gly Arg Leu Pro Ser Lys Pro Lys Ser Pro             340 345 350 Gln Asp Pro Ser Pro Pro Ser Pro Pro Val Ser Leu Ile Ser Ala Leu         355 360 365 Val Arg Ala His Val Asp Ser Asn Pro Ala Met Thr Ser Leu Asp Tyr     370 375 380 Ser Arg Phe Gln Ala Asn Pro Asp Tyr Gln Met Ser Gly Asp Asp Thr 385 390 395 400 Gln His Ile Gln Gln Phe Tyr Asp Leu Leu Thr Gly Ser Met Glu Ile                 405 410 415 Ile Arg Gly Trp Ala Glu Lys Ile Pro Gly Phe Ala Asp Leu Pro Lys             420 425 430 Ala Asp Gln Asp Leu Leu Phe Glu Ser Ala Phe Leu Glu Leu Phe Val         435 440 445 Leu Arg Leu Ala Tyr Arg Ser Asn Pro Val Glu Gly Lys Leu Ile Phe     450 455 460 Cys Asn Gly Val Val Leu His Arg Leu Gln Cys Val Arg Gly Phe Gly 465 470 475 480 Glu Trp Ile Asp Ser Ile Val Glu Phe Ser Ser Asn Leu Gln Asn Met                 485 490 495 Asn Ile Asp Ile Ser Ala Phe Ser Cys Ile             500 505 510 Thr Glu Arg His Gly Leu Lys Glu Pro Lys Arg Val Glu Glu Leu Gln         515 520 525 Asn Lys Ile Val Asn Cys Leu Lys Asp His Val Thr Phe Asn Asn Gly     530 535 540 Gly Leu Asn Arg Pro Asn Tyr Leu Ser Lys Leu Leu Gly Lys Leu Pro 545 550 555 560 Glu Leu Arg Thr Leu Cys Thr Gln Gly Leu Gln Arg Ile Phe Tyr Leu                 565 570 575 Lys Leu Glu Asp Leu Val Pro Pro Ala Ile Asp Lys Leu Phe             580 585 590 Leu Asp Thr Leu Pro Phe         595 <210> 16 <211> 2599 <212> DNA <213> human <400> 16 gcacctggcc tgggctcctg cctccagaga gcctggcccc aaggaagagt ctagtaagct 60 tagttcccat cgggcttcca tgaaagcaca actggcccgg caggaaaccg aattaaaaag 120 caatatttgt atcagtggaa gacatttgct gaaaggttaa atccacatcc ggcagtgtgg 180 gccatgagcc tccggcgtgg tgttcatcag gcatgtctct cctcctggcc tgggcacctg 240 agcactgggg ccgccctggg cagagctggg gcggggtgct ggggggcctg gagctgcctc 300 accgagggat cctcagcagc cgaccctggg ggaggcaaat gagactcttt ctggggacct 360 tgaggggagc tcgggggagc catgcagagc ttcaccaggc ctggacactg ggcatggagg 420 ctgggccacc caagggccat caccagggac tcaggtgggt gggcctcagc cctgggtgac 480 agaagctcac gggccgcagg gcgaggccag aggctgagcc ttcaggctga ggtcttggag 540 gcaaatccct ccaacgccct tctgagcagg cacccagacc tactgtgggc aggacccaca 600 ggaggtggag gcctttgggg aacactgtgg aggggcatag catctccgag agaggacagg 660 gtctgcactg ggtgctgaga gacagcaggg gccgagcggt aggcttccct gcccccaggg 720 atgttccaga ggagcgcaag ggaggggcat taatatcgtg gcaagaaagg gcaggcattg 780 caggtgagc agcgacggaa ctgggttttg tgggatgcat aggagttcac ccggataaga 840 ggtgggtgag gaatgacact gcaaaccggg gatcacggag ccccaaatcc ttctgggcca 900 ggaagtggga agggttgggg ggtcttccct ttgctttgac tgagcactca gcctgcctgc 960 agagggcagc gaggagccac ggaggggtgt gggacaggga tgccatggct gaagcagttt 1020 taggaaaggt cccaggggct attgttgaag agagaacggg gagcggggag tcccacagct 1080 gacaggagca gagtgggccc tgagagatgc cagctctggc tgccacagtg accagccggg 1140 gtaggccttc gagaagtcag ggagcgtcta gggcttctgg ctcctgctgg gcccagggtg 1200 tcatcttggg ctgccaacac cagaaagccc agcagataca ggaagcccca agccctgtcg 1260 gaaacggttc ttctccagga gggacagcgg tggcagcgtt cagccgcagg ccatgcactc 1320 tggggccacg tccttccctc tgtacagtcc agcattgtca aggcaggctc tggccatctc 1380 tgctgacccc agagggatgg ggaggcctcc ccttccacca gaagggccag aagccaccct 1440 gggcaggggc atcactctcc ctgggtgggg cagcggctgg gagcaggagg tgccagtggg 1500 cgtgggctgg atgcgggtgc ctgcggggcg gacatggaac ttgggggagg ctctaggctg 1560 gggttgtcct caagggagtt ctcaggtcac cccagggtca ccctcaaccc ggggcctggt 1620 ggggtagagg agaaactgca aaggtctctc caaggggaag gcatcagggc cctcagcact 1680 gagggacgtg cgtgctcttt aaagaagggg ccacaggacc ccgagggaag ccaggagcta 1740 gcagtgggcc atagaggggc tgagtggggt gggtggaagc cgtccctggc cctggtcgcc 1800 ctggcaaccc tggtggggac tgtgatgcag gaggtggcag ccatttggaa acgcgtggcg 1860 tctccttaga gatgtcttct tcagcctccc agggtcctcc acactggaca ggtgggccct 1920 cctgggacat tctggacccc acggggcgag cttgggaagc cgctgcaagg gccacacctg 1980 cagggcccgg gggctgtggg cagatggcac tcctaggaac cacgtctatg agacacacgg 2040 cctggaatct tctggagaag caaacaaatt gcctcctgac atctgaggct ggaggctgga 2100 ttccccgtct tggggctttc tgggtcggtc tgccacgagg ttctggtgtt cattaaaagt 2160 gtgcccctgg gctgccagaa agcccctccc tgtgtgctct cttgagggct gtggggccaa 2220 ggggaccctg gctgtctcag ccccccgcag agcacgagcc cctggtcccc gcaagcccgc 2280 gggctgagga tgattcagac agggctgggg agtgaaggca attagattcc acggacgagc 2340 cctttctcct gcgcctccct ccttcctcac ccacccccgc ctccatcagg cacagcaggc 2400 aggggtgggg gatgtaagga ggggaaggtg ggggacccag agggggcttt gacgtcagct 2460 cagcttataa gaggctgctg ggccagggct gtggagacgg agcccggacc tccacactga 2520 gccatgccca cccccgacgc caccacgcca caggccaagg gcttccgcag ggccgtgtct 2580 gagctggacg ccaagcagg 2599 <210> 17 <211> 2306 <212> DNA <213> mouse <400> 17 ttaggccagg tgctacttga gagagctcag acacagacaa aggtctggag agcacatgtc 60 ctccaccccc acctagcttc tgttgcaagc acctccagcc gagacaagag aacgaattaa 120 aaagcaatat ttgtgtcagt gtaagacatt tgccgaaagg ttaaatccac attcgtgttg 180 ctgcagagca gccccctatg caggatttgt tagatacagc tccgtcctac cctgtgccag 240 ctgagcaaac gccaggctgg gtggggtgga acccagcctg ggtttgcctc accctgcaat 300 ccccccagca ccctctaaag gaggaccctg tggtgggcat gcagacctag ggactgggca 360 tagataacct ttgggtttgg gcaacagccc ccactcctca ggattgaagg ctaaggtgca 420 gccagctctg ccttcatggt gggaatgtct ccacgtgacc cctttctggg ctgtggagaa 480 cactcagaga agagtcctgg gatgccaggc aggccaggga tgtgctgggc atgttgagac 540 aggagtgggc taagccagca gagttgctga cccaggaaga gttcagaaag gggcatggaa 600 catggggagg ggtccatagt gagagagagc aggcagtgca gagtaaatag tccctgagct 660 gggggttatg ggatttgcag gagcttgctc agagaaggca gaggagagat gctgcgccaa 720 gctgggtatc acagagcctc agactcctgg aacaggaact gtgggggtca ggtcagcagg 780 ggaggttagg gagtgttccc tttgtactga cttagcattt atcctgcttc taggggggaa 840 ggggggccag tgggggatgc acagcaaggc agtgatgtgg caggcagcct gcgggagctc 900 ctggttcctg gtgtgaaaaa gctgggaagg aagagggctg ggtctggtaa gtacagcagg 960 cagttggctc ctgagagtcc aagccctgtc tagagggtgg agtgagattt cagagggaga 1020 gctaaacggg gtgggggctg gggagtccag gcttctggct cctgctaata ctcagtgtgc 1080 tgggtcctca gaacctcagg gtggccattt tcagggtgag agctctgtcc tttggcactt 1140 ctgcagactc cagtatccag aggaataaag atggtactct tcctcagttc ccttagtgag 1200 aggacacctt tctctgaagg gcttgggcag ttgtcctgaa ccattgcctg aaggaaggac 1260 ttgactccag ggacatagaa tgggctcagc ataagtcccc tgtagtagag aaaggtcccc 1320 tctctggtct ccttagagat cctgtttcct tggctgagga agctagggtg gatctttgtg 1380 taagtgggtg tggatgctca ctggaaatca aaaggcccct tggtgttaga ccttggggtg 1440 ccatgggaga gttgatcact gagtgcgccc ttacatgggg gccagctgag aatggggctg 1500 cctctagctc gagaccatga tgcagggagt gagtggggga gttcaggata ctcttaacta 1560 aagcagaggt ctgtcccccc agggagggga ggtcagaaga ccctagggag atgccaaagg 1620 ctagggttgg caccatgttg caggctgtgt cttcaaggag atgataatca gaggaatcga 1680 acctgcaaaa gtgggccagt cttagataca ctatagagga ataatcttct gaaacattct 1740 gtgtctcata ggacctgcct gaggacccag ccccagtgcc agcacataca ctggggcagt 1800 gagtagatag tatactttgt tacatgggct ggggggacat ggcctgtgcc ctggagggga 1860 cttgaagaca tccaaaaagc tagtgagagg gctcctagat ttatttgtct ccaagggcta 1920 tatatagcct tcctaacatg aacccttggg taatccagca tgggcgctcc catatgccct 1980 ggtttgatta gagagctcta gatgtctcct gtcccagaac accagccagc ccctgtcttc 2040 atgtcgtgtc tagggcggag ggtgattcag aggcaggtgc ctgcgacagt ggatgcaatt 2100 agatctaatg ggacggaggc ctctctcgtc cgtcgccctc gctctgtgcc cacccccgcc 2160 tccctcaggc acagcaggcg tggagaggat gcgcaggagg taggaggtgg gggacccaga 2220 ggggctttga cgtcagcctg gcctttaaga ggccgcctgc ctggcaaggg ctgtggagac 2280 agaactcggg accaccagct tgcact 2306 <210> 18 <211> 2462 <212> DNA <213> rat <400> 18 ctagcacaga tgccttagat cttggcacaa tgtagtcagc cagctccgtg tgtgtgtgtg 60 tgtgtttgca tgtatctcac agacagtgca caatggcctg gatgtgaaca gaggcaagag 120 tctgggccag cagttgtctc ccaggagggt ccaaagacat cgtattttca agtttaggcc 180 aggtgctcac ttgggtgagc tcagacacag acaaaggtct ggagagcaca cattccccac 240 ccccacccag ctcctatgca agcacctcca gccgagacaa gaaaacgaat taaaaagcaa 300 tatttgtgtc agcgtaagac atttgccgaa aggttaaatc cacactcgtg gtgctgcaca 360 gcagccccct gtgcaggatt tgttaggcac agctccctcc taccccgtgc cacctgagca 420 aatgccaggc tgggtgggct ggaaccagcc tgggcttgcc tcaccctgga atccccagca 480 ccctccaaag gaggaccctg ggagtgggca tagacgccct tcaggtgtgg gcaacagccc 540 ccagtcctca ggatgaaagg ctaaggtgca gccagctctg ccttcacggt gggaatgtct 600 ctatgtgagc cctttctggg ctgtgaagaa cgctctgaga agggtcctgg gaccctggat 660 aggccagagc tgtgctgggc atgtagagac aggagtgggc taaagcagca aaggcactga 720 ccaaggaaga gttcagagag gagcgtggaa tatggggagg ggttcatagt aagagagagc 780 aggcagtgga gagtaaatag tcactgagcc ggggtttatg gggtttgtag gagcttactc 840 agagaaagta gatgagagat gccatgccag tctgagtatc acagagcccc aggctctcct 900 gggaacggaa ctgtgagggc cagaaggtca gcaagggagg ttagggagag ttccttttgt 960 actgactcag catttatcct gctcccaggg ggcaatgggg gccagtgagg gatgcagagc 1020 aaggcagtga tgtggcaggc agttcctgtt gtgaaagagc tgggaaggga gcgggctggg 1080 cctggtacgt acagcaggcc atttctgagg gtccgagtgc tgtctaggag gtgcagtgag 1140 acttcagtga tcagccagaa cagaagctaa gcggggtggg gactgcgagt tcaggcttct 1200 gggtcttgca aatatccaga atgctaaatc ctcagaaccc cagggtggcc attttcagag 1260 tgggttttgt cctttgggca cttgtgcaga ctccaatatc cagagggata aggatggtac 1320 tcttcagtac ccttagtgag aggacacttt tctctgaagg gcttgaatgt gccgagccat 1380 tacctgaagg aaggaaatga ctccagggac ataggatggg cccagcacaa ctcacctgct 1440 acagagaaag gtcccctccc tggtctcctt agagatcctg tttccctggc tgaggaagct 1500 agggtggatc tttgtgtaag tgggtgtgga tgctaactgg aaaacaaaag gtcacttact 1560 gttagacctc ggggtaccat ggaagagatg atcactgagt gtgcccttac atggggacca 1620 gctgagaatg gggctaccac tagctcgaga ccatgataca gggaataagt gtgcatttgg 1680 gggtagggag tggctcagaa tactcttaac caaagcagag gtttgctccc acaggaaggt 1740 gggtcagaa ggccttaggg agctgccagg ggctagggtt ggcaccatct cccaggctgt 1800 gtctttaagg agatgataat cagagggata gaaccttgca aaagtgggcc agtcttggga 1860 atactataga ggaatagcct tctggaacat tctgtgtctc ataggacctg cctggggatc 1920 cagccccagt gccagcacat ataccgactg gggcagtgaa tagatagtac actttgttac 1980 atgggctggg gggaacatgg cccatgtcct ggaggggact ttatgacaga catccaaaaa 2040 tccagtgaga gggcttctag atttgtctcc aaaggttata gttctaacat gagcccttag 2100 gaaatccagc atggttctcc ctgtgtgccc tggtttggtt agagagctct agcggtctcc 2160 tgtcccacag aataccagcc agcccctgcc ctacgtcgtg cctcgggctg agggtgattc 2220 agaggcaggt gcctgtgaca gtggatgcaa ttagatctaa tgggacggag gcctttctcg 2280 tcgccctcgc tccatgccca cccccgcctc cctcaggcac agcaggcgtg gagaggatgc 2340 gcaggaggta ggaggtgggg gacccagagg ggctttgacg tcagcctggc ctttaaagag 2400 ggcgcctgcc tggcgagggc tgtggagaca gaactcggga ccaccagagg aattcgatat 2460 ca 2462 <210> 19 <211> 21 <212> DNA <213> human <400> 19 agtgatgcca aggacaagct c 21 <210> 20 <211> 20 <212> DNA <213> human <400> 20 gctaatggca ctcagtgctt 20 <210> 21 <211> 20 <212> DNA <213> human <400> 21 agggcacaag caacattacc 20 <210> 22 <211> 20 <212> DNA <213> human <400> 22 cacaggcgtg cactccatag 20 <210> 23 <211> 20 <212> DNA <213> human <400> 23 caagcacctt ccttccaatg 20 <210> 24 <211> 20 <212> DNA <213> human <400> 24 gattgcagtc cacaccactg 20 <210> 25 <211> 19 <212> DNA <213> human <400> 25 atgctcgcca tccacaaga 19 <210> 26 <211> 20 <212> DNA <213> human <400> 26 gcggaatcga atgggagaat 20 <210> 27 <211> 23 <212> DNA <213> human <400> 27 tgaagagagc ggacaaggag atc 23 <210> 28 <211> 24 <212> DNA <213> human <400> 28 tctggagtta agaaatcgga gctg 24 <210> 29 <211> 20 <212> DNA <213> human <400> 29 gggagaatca tggaccagaa 20 <210> 30 <211> 20 <212> DNA <213> human <400> 30 ccgtaaggca tcattggact 20

Claims (17)

(a) contacting a sample to be analyzed with an REV-ERBα protein represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 and a TH protein represented by SEQ ID NO: 4, SEQ ID NO: ;
(b) measuring the amount or activity of the protein; And
(c) it is confirmed that the amount or activity of the REV-ERB [alpha] protein is decreased and the amount or activity of the TH protein is increased; Or REV-ERBa protein is increased and the amount or activity of the TH protein is decreased, it is determined that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease. A method for preventing and / or screening an emotional disorder and / or poisoning disease.
(a) contacting a sample to be analyzed with a cell comprising the REV - ERB alpha gene of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 and the TH gene of SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12 step;
(b) measuring the expression level of the gene; And
(c) the expression amount of the REV - ERB alpha gene is increased and the TH The expression level of the gene is confirmed to be decreased; Or the expression level of the REV-ERB alpha gene is decreased and TH A method for screening for a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease, .
(a) contacting a sample to be analyzed with a cell comprising the REV - ERB alpha gene of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 and TH protein of SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 step;
(b) measuring the expression level of the gene and the amount or activity of the protein; And
(c) it is confirmed that the expression amount of the REV - ERB alpha gene is increased and the amount or activity of the TH protein is decreased; Or REV - ERB alpha gene is decreased and the amount or activity of the TH protein is increased, it is determined that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease , A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease.
(a) an REV-ERBα protein represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, a NURR1 protein represented by SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15, and SEQ ID NO: Contacting the sample to be analyzed with a cell containing the R / N1 region and the R / N2 region of the TH promoter represented by SEQ ID NO: 18;
(b) measuring a change in binding force of each of the REV-ERBα protein and the NURR1 protein to the R / N1 and R / N2 regions before and after contacting the sample; And
(c) screening for a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of: if the change in the binding force is confirmed, determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / Way.
5. The method according to any one of claims 1 to 4,
(ATCC, CRL-11179) or MN9D cell line (ATCC, CRL-1721), Cath.a cell line And / or an agent for screening for a therapeutic agent for preventing and / or treating an addictive disorder.
An antisense or siRNA (small interference RNA) oligonucleotide having a sequence complementary to the nucleotide sequence shown in SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 as an active ingredient, and / Therapeutic malignant composition.
An agamic composition for preventing and / or treating an emotional disorder and / or poisoning disease, comprising an agonist or antagonist of REV-ERBa.
8. The pharmaceutical composition according to claim 7, wherein the agonist of REV-ERBa is GSK41122 and the antagonist is SR8278.
5. The method according to any one of claims 1 to 4,
Wherein the emotional disorder and poisoning disorder are depression, bipolar disorder, seasonal mood disorder, or panic disorder.
9. The method according to any one of claims 6 to 8,
Wherein the emotional disorder and poisoning disorder are depression, bipolar disorder, seasonal mood disorder, or panic disorder.
(a) a sample to be analyzed in a cell comprising an REV-ERBα protein represented by an amino acid sequence having 90% or more homology with SEQ ID NO: 2 and a TH protein represented by an amino acid sequence having 90% or more homology with SEQ ID NO: 5 ;
(b) measuring the amount or activity of the protein; And
(c) it is confirmed that the amount or activity of the REV-ERB [alpha] protein is decreased and the amount or activity of the TH protein is increased; Or REV-ERB [alpha] protein is increased and the amount or activity of the TH protein is found to decrease,
A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease.
(a) an REV-ERBa protein, or an active fragment, derivative or analogue thereof; And a TH protein, or an active fragment, derivative or analog thereof, with a sample to be analyzed;
(b) measuring the amount or activity of the protein, or an active fragment, derivative or analog thereof; And
(c) it is confirmed that the amount or activity of the REV-ERBα protein, or an active fragment, derivative or analog thereof, is decreased and that the amount or activity of the TH protein, or an active fragment, derivative or analogue thereof, is increased; Or REV-ERB [alpha] protein, or an active fragment, derivative or analog thereof, and the amount or activity of the TH protein, or active fragment, derivative or analog thereof, is decreased,
A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease.
(a) an REV - ERB alpha gene represented by a nucleotide sequence having 90% or more homology with SEQ ID NO: 8 and a TH gene represented by a nucleotide sequence having 90% or more homology with SEQ ID NO: 11 Contacting the sample;
(b) measuring the expression level of the gene; And
(c) the expression amount of the REV - ERB alpha gene is increased and the TH The expression level of the gene is confirmed to be decreased; Or the expression level of the REV-ERB alpha gene is decreased and TH When it is confirmed that the expression amount of the gene is increased,
A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disease.
(a) contacting a sample to be analyzed with a cell comprising an REV - ERB alpha gene and a TH protein, or an active fragment, derivative or analogue thereof, represented by the nucleotide sequence having 90% or more homology with SEQ ID NO: 8;
(b) measuring the amount of expression of the gene and the amount or activity of the protein, or an active fragment, derivative or analog thereof; And
(c) it is confirmed that the expression amount of the REV - ERB alpha gene is increased and the amount or activity of the TH protein, or an active fragment, derivative or analog thereof is decreased; Or REV - ERB alpha gene is decreased and it is confirmed that the amount or activity of the TH protein, active fragment, derivative or analog thereof is increased,
A method for screening a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / or a poisoning disorder.
(a) contacting a sample to be analyzed with cells comprising the REV-ERBα protein, or an active fragment, derivative or analogue thereof, and the R / N1 and R / N2 regions of the TH promoter;
(b) measuring the change in the binding force of each of the REV-ERBα protein, or an active fragment, derivative or analogue thereof, and the NURR1 protein to the R / N1 and R / N2 sites before and after contacting the sample; And
(c) screening for a preventive and / or therapeutic agent for an emotional disorder and / or poisoning disease, comprising the step of: if the change in the binding force is confirmed, determining that the sample is a preventive and / or therapeutic agent for an emotional disorder and / Way.
The method according to any one of claims 11 to 15,
(ATCC, CRL-11179) or MN9D cell line (ATCC, CRL-1721), Cath.a cell line And / or a method for screening a therapeutic agent for the prevention and / or treatment of a poisoning disorder.
As a method for diagnosing an emotion disorder or poisoning disease performed in vitro,
(a) The binding strengths to the R / N1 and R / N2 regions of the TH promoter of each protein of REV-ERBα and NURR1 were determined by CT00 And CT12; And
(b) determining the binding force measured in step (a) as the R / N1 region and the R / N2 region of the TH promoter of each protein of REV-ERBα and NURR1, measured on CT00 and CT12, And comparing the binding force to each site, wherein the binding force between NURR1 and R / N1 is increased in CT12, judging the patient to be an emotional disorder or poisoning patient.

Images